Synthetic method of fluoroalkylamine compound
The synthesis of difluoroalkylamine compounds from non-activated difluoroalkyl halides using a nickel-based coupling method addresses the limitations of existing methods, offering a straightforward and effective route for broader application in medicinal chemistry.
Patent Information
- Application Number
- CN202410694939.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-06-01
- Filing Date
- 2024-05-31
- Publication Date
- 2024-12-03
AI Technical Summary
There are limited methods for synthesizing difluoroalkylamine compounds from non-activated difluoroalkyl halides, which are more stable and cheaper than traditional nucleophilic difluoroalkylating agents, limiting their application in medicinal chemistry.
A method involving the coupling of compounds of formula II and III in a solvent with a nickel salt or nickel complex and a ligand, such as MHMDS, to synthesize fluoroalkylamine compounds.
Provides a simple and efficient synthesis of difluoroalkylamine compounds, expanding their applicability in medicinal chemistry.
Smart Images

Figure CN119059929A_ABST
Abstract
Description
[0001] This application claims the priority of Chinese patent application No. 202310639312.6 filed on June 1, 2023. This application cites the entire text of the above Chinese patent application. Technical Field
[0002] The invention relates to a method for synthesizing fluoroalkylamine compounds. Background Art
[0003] Difluoroalkylamine structures have important applications in bioactive molecules. Some bioactive molecules containing difluoroalkylamine structures are listed below. Introducing fluorine atoms into the α position of the amine will change the alkalinity of the amine, thereby affecting the hydrogen bonding between the amine and the organism, thus bringing different biological activities. For example, the introduction of difluoromethylene into the side chain of the natural product Rhodopeptins can effectively improve the solubility of the bioactive molecule and reduce its toxicity while maintaining its antibacterial activity (Nakayama, K.; Kawato, HC; Inagaki, H.; Nakajima, R.; Kitamura, A.; Someya, K.; Ohta, T. Org. Lett. 2000, 2, 977-980); after the introduction of difluoroalkylamine side chain, the efficacy of the anti-tumor drug docetaxel is 2 to 5 times that of the non-fluorinated parent (Uoto, K.; Ohsuki, S.; Takenoshita, H.; Ishiyama, T.; Iimura, S.; Hirota, Y.; Mitsui, I.; Terasawa, H.; Soga, T. CHEMICAL & PHARMACEUTICAL BULLETIN 1997, 45, 1793-1804).
[0004]
[0005] Currently, difluoroalkylamine structures are mainly constructed by the addition of nucleophilic difluoroalkylating agents to imines as shown below.
[0006]
[0007] According to the different types of difluoroalkyl nucleophiles, they can be divided into zinc reagents, silicon reagents, boron reagents and indium reagents. Due to the poor stability of difluoroalkyl nucleophiles, these reagents generally need to introduce π systems such as carbonyl, alkenyl and alkynyl groups at the ortho position of the difluoromethylene. For non-activated difluoroalkyl-substituted amine structures, it is difficult to use a similar strategy to synthesize them because their corresponding fluorine-containing nucleophiles are extremely unstable.
[0008] At the same time, the existing reports on the synthesis of non-activated difluoroalkylamine structures are also very limited. In 2010, Zhou Yonggui's research group reported the asymmetric hydrogenation of fluoroalkylimines under palladium catalysis (Chen, M.-W.; Duan, Y.; Chen, Q.-A.; Wang, D.-S.; Yu, C.-B.; Zhou, Y.-G. Org. Lett. 2010, 12, 5075-5077). Among them, there is only one example of the synthesis of non-activated difluoroalkylamines, and the synthesis of the substrate of difluoroalkylimine is relatively cumbersome.
[0009] In 2016, Dilman's research group reported the reductive difluoroalkylation reaction of nitroketones under photocatalytic conditions (Supranovich, VI; Levin, VV; Struchkova, MI; Dilman, AD Org. Lett. 2018, 20, 840-843.). The nitrogen oxides generated by this method are then reduced by zinc powder to obtain non-activated difluoroalkylamine products. However, the non-activated difluoroalkyl iodide substrate is limited and not universal.
[0010] Compared with nucleophilic difluoroalkylating agents, non-activated difluoroalkyl halides are cheaper, easier to obtain, less susceptible to stability, and have richer structures. If it is possible to achieve a one-step synthesis of difluoroalkylamine structures starting from non-activated difluoroalkyl halides, it will provide an efficient and simple method for obtaining such structures, thereby further promoting their application in medicinal chemistry.
[0011] Therefore, it is very important to develop a method for preparing difluoroalkylamine compounds using non-activated difluoroalkyl halides. Summary of the invention
[0012] The technical problem to be solved by the present invention is to overcome the defect that there are few methods for preparing difluoroalkylamine compounds from non-activated difluoroalkyl halides. To this end, the present invention provides a method for synthesizing fluoroalkylamine compounds. The synthesis method provided by the present invention has good applicability, is easy to operate, and has broad application prospects.
[0013] The present invention provides a method for preparing a compound of formula I, comprising the following steps: in a solvent, under the action of MHMDS, a nickel salt or a nickel complex and a ligand, coupling a compound of formula II and a compound of formula III to obtain the compound of formula I;
[0014]
[0015] in,
[0016] M is Na, K or Li;
[0017] The ligand is a compound represented by formula L
[0018]
[0019] R 3 H or
[0020]
[0021] R 4 is H or C1-C6 alkyl;
[0022] X is Cl, Br or I;
[0023] Y is fluorenyl;
[0024] L1 and L2 are each independently a C1-C6 alkylene group or a chemical bond;
[0025] R 1 For hydrogen, halogen, cyano, hydroxyl, C6~C 14 Aryl, C5~C 12 Heteroaryl, C3~C 12 Cycloalkyl, C3~C 12 Heterocycloalkyl, -NHR 1-1 、-OR 1-2 , -(C=O)-R 1-3 , by one or more R 1-4 Replacement C3~C 12 Heterocycloalkyl, By one or more R 1b Substituted C6~C 14 Aryl or one or more R 1c Substituted C5~C 12 heteroaryl;
[0026] Each R 1-4 Each is independently an amino protecting group;
[0027] R 1-1 and R 1-2 Each independently is a C1-C6 alkyl group, 1-1-1 Substituted C1-C6 alkyl, -Si(R 1 -1-2 )3 or -(C=O)-R 1-1-3 ;
[0028] Each R 1-1-1 Each independently is C6~C 14 Aryl or C5~C 12 heteroaryl;
[0029] Each R 1-1-2Each is independently a C1-C6 alkyl group;
[0030] R 1-3 and R 1-1-3 Each independently is a C1-C6 alkyl group, 1-3-1 Substituted C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C 14 Aryl, C5~C 12 Heteroaryl, one or more R 1-3-2 Replacement C6~C 14 Aryl, one or more R 1-3-3 Replacement C5~C 12 Heteroaryl or
[0031] Each R 1-3-1 Each of C6~C 14 Aryl, one or more R 1-3-1-1 Replacement C6~C 14 Aryl, C5~C 12 Heteroaryl or one or more R 1-3-1-2 Replacement C5~C 12 heteroaryl;
[0032] Each R 1-3-1-1 and R 1-3-1-2 Each independently represents a C1-C6 alkyl group, a C1-C6 alkoxy group, a C1-C6 alkylthio group or -(C=O)-R a ;
[0033] R a C6~C 14 Aryl, C5~C 12 Heteroaryl, C6~C 14 Aryl or C5~C 12 heteroaryl;
[0034] Each R 1-3-2 are each independently cyano, hydroxyl or halogen;
[0035] Each R 1-3-3 Each independently is a C1-C6 alkyl, a C6-C 14 Aryl, C5~C 12 Heteroaryl, one or more R 1 -3-3-1 Replacement C6~C 14 Aryl or one or more R 1-3-3-2 Replacement C5~C 12 heteroaryl;
[0036] Each R 1-3-3-1 and R1-3-3-2 Each is independently cyano, hydroxyl, halogen, C1-C6 alkylthio or C1-C6 alkoxy;
[0037] R 1a is C1~C6 alkyl or -Si(R 1a-1 )3, each R 1a-1 Each is independently a C1-C6 alkyl group;
[0038] R 1b and R 1c Each independently is C6-C 14 Aryl or C5-C 12 heteroaryl;
[0039] R 1d and R 1e Each independently is H or C1-C6 alkyl;
[0040] R 2 is hydrogen, halogen, cyano, hydroxyl, C1-C6 alkyl, C2-C6 alkenyl, C6-C 14 Aryl, C5~C 12 Heteroaryl, C3~C 12 Cycloalkyl, C3~C 12 Heterocycloalkyl, C3~C 12 Cycloalkenyl, with one or more R 2-1 Replacement C6~C 14 Aryl, one or more R 2-2 Replacement C5~C 12 Heteroaryl, C1-C6 alkoxy, C1-C6 alkylthio, -OR 2-3 or one or more R 2-4 Replacement C3~C 12 Heterocycloalkyl; each R 2-4 Each is independently an amino protecting group;
[0041] Each R 2-1 and R 2-2 Each is independently -(C=O)-O-C1~C6 alkyl, C1~C6 alkyl, cyano, halogen or hydroxyl;
[0042] R 2-3 is C1-C6 alkyl or is replaced by one or more R 2-3-1 Substituted C1-C6 alkyl;
[0043] Each R 2-3-1 Each independently is C6~C 14 Aryl or C5~C 12 heteroaryl;
[0044] Each of the C5~C 12Heteroaryl and C3~C 12 In the heterocycloalkyl group, the heteroatom is selected from one or more of N, O and S, and the number of the heteroatoms is 1, 2 or 3.
[0045] In one embodiment, the preparation method of the compound of formula I comprises the following steps: in a solvent, under the action of MHMDS, a nickel salt or a nickel complex and a ligand, a compound of formula II and a compound of formula III are coupled to obtain the compound of formula I;
[0046]
[0047] in,
[0048] M is Na, K or Li;
[0049] The ligand is a compound represented by formula L
[0050]
[0051] R 3 H or
[0052]
[0053] R 4 is H or C1-C6 alkyl;
[0054] X is Cl, Br or I;
[0055] Y is fluorenyl;
[0056] L1 and L2 are each independently a C1-C6 alkylene group or a chemical bond;
[0057] R 1 For hydrogen, halogen, cyano, hydroxyl, C6~C 14 Aryl, C5~C 12 Heteroaryl, C3~C 12 Cycloalkyl, C3~C 12 Heterocycloalkyl, -NHR 1-1 、-OR 1-2 , -(C=O)-R 1-3 or one or more R 1-4 Replacement C3~C 12 Heterocycloalkyl;
[0058] Each R 1-4 Each is independently an amino protecting group;
[0059] R 1-1 and R 1-2 Each independently is a C1-C6 alkyl group,1-1-1 Substituted C1-C6 alkyl, -Si(R 1 -1-2 )3 or -(C=O)-R 1-1-3 ;
[0060] Each R 1-1-1 Each independently is C6~C 14 Aryl or C5~C 12 heteroaryl;
[0061] Each R 1-1-2 Each is independently a C1-C6 alkyl group;
[0062] R 1-3 and R 1-1-3 Each independently is a C1-C6 alkyl group, 1-3-1 Substituted C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C 14 Aryl, C5~C 12 Heteroaryl, one or more R 1-3-2 Replacement C6~C 14 Aryl or one or more R 1-3-3 Replacement C5~C 12 heteroaryl;
[0063] Each R 1-3-1 Each of C6~C 14 Aryl, one or more R 1-3-1-1 Replacement C6~C 14 Aryl, C5~C 12 Heteroaryl or one or more R 1-3-1-2 Replacement C5~C 12 heteroaryl;
[0064] Each R 1-3-1-1 and R 1-3-1-2 Each independently represents a C1-C6 alkyl group, a C1-C6 alkoxy group, a C1-C6 alkylthio group or -(C=O)-R a ;
[0065] R a C6~C 14 Aryl, C5~C 12 Heteroaryl, C6~C 14 Aryl or C5~C 12 heteroaryl;
[0066] Each R 1-3-2 are each independently cyano, hydroxyl or halogen;
[0067] Each R 1-3-3Each independently is a C1-C6 alkyl, a C6-C 14 Aryl, C5~C 12 Heteroaryl, one or more R 1 -3-3-1 Replacement C6~C 14 Aryl or one or more R 1-3-3-2 Replacement C5~C 12 heteroaryl;
[0068] Each R 1-3-3-1 and R 1-3-3-2 Each is independently cyano, hydroxyl, halogen, C1-C6 alkylthio or C1-C6 alkoxy;
[0069] R 2 is hydrogen, halogen, cyano, hydroxyl, C1-C6 alkyl, C2-C6 alkenyl, C6-C 14 Aryl, C5~C 12 Heteroaryl, C3~C 12 Cycloalkyl, C3~C 12 Heterocycloalkyl, C3~C 12 Cycloalkenyl, with one or more R 2-1 Replacement C6~C 14 Aryl, one or more R 2-2 Replacement C5~C 12 Heteroaryl, C1-C6 alkoxy, C1-C6 alkylthio, -OR 2-3 or one or more R 2-4 Replacement C3~C 12 Heterocycloalkyl; each R 2-4 Each is independently an amino protecting group;
[0070] Each R 2-1 and R 2-2 Each is independently -(C=O)-O-C1~C6 alkyl, C1~C6 alkyl, cyano, halogen or hydroxyl;
[0071] R 2-3 is C1-C6 alkyl or is replaced by one or more R 2-3-1 Substituted C1-C6 alkyl;
[0072] Each R 2-3-1 Each independently is C6~C 14 Aryl or C5~C 12 heteroaryl;
[0073] Each of the C5~C 12 Heteroaryl and C3~C 12 In the heterocycloalkyl group, the heteroatom is selected from one or more of N, O and S, and the number of the heteroatoms is 1, 2 or 3.
[0074] In a certain scheme, in the preparation method of the compound represented by formula I, the definitions of certain groups are as described below, and the definitions of the remaining groups are as described in any other scheme (hereinafter referred to as "a certain scheme"): M is Li.
[0075] In one plan, For example
[0076] In one plan, For example
[0077] In one scheme, R 3 H or For example, H.
[0078] In one scheme, R 4 is H or C1-C6 alkyl, for example, C1-C6 alkyl.
[0079] In one embodiment, the compound represented by formula L is For example Preferably
[0080] In one embodiment, the nickel salt is Ni(T)2 or a DME complex of Ni(T)2, where T is a halogen, for example, a DME complex of Ni(T)2, where T is a halogen.
[0081] In one embodiment, the coupling reaction is carried out under the action of a nickel salt and a ligand, for example, a DME complex of Ni(T)2 and a ligand.
[0082] In one embodiment, the nickel complex is a nickel COD complex.
[0083] In one embodiment, X is I or Br.
[0084] In one scheme, R 1 Halogen, cyano, C6~C 14 Aryl, C3~C 12 Cycloalkyl, C3~C 12 Heterocycloalkyl, with one or more R 1-4 Replacement C3~C 12 Heterocycloalkyl, -NHR 1-1 、-OR 1-2 or -(C=O)-R 1-3 .
[0085] In one scheme, R 1 Halogen, cyano, C6~C 14 Aryl, C3~C 12 Cycloalkyl, C3~C 12Heterocycloalkyl, with one or more R 1-4 Replacement C3~C 12 Heterocycloalkyl, -NHR 1-1 、-OR 1-2 , -(C=O)-R 1-3 , or one or more R 1b Substituted C6~C 14 Aryl.
[0086] In one scheme, R 1-1 and R 1-2 Each independently is one or more R 1-1-1 Substituted C1-C6 alkyl, -Si(R 1-1-2 )3 or -(C=O)-R 1-1-3 .
[0087] In one scheme, each R 1-1-1 Each independently is C6~C 14 Aryl.
[0088] In one scheme, R 1-3 and R 1-1-3 Each independently is one or more R 1-3-1 Substituted C1-C6 alkyl, C1-C6 alkoxy, one or more R 1-3-2 Replacement C6~C 14 Aryl or one or more R 1-3-3 Replacement C5~C 12 Heteroaryl.
[0089] In one scheme, R 1-3 and R 1-1-3 Each independently is one or more R 1-3-1 Substituted C1-C6 alkyl, C1-C6 alkoxy, one or more R 1-3-2 Replacement C6~C 14 Aryl, one or more R 1-3-3 Replacement C5~C 12 Heteroaryl or
[0090] In one scheme, each R 1-3-1 Each independently is one or more R 1-3-1-2 Replacement C5~C 12 Heteroaryl.
[0091] In one scheme, each R 1-3-1-1 and R 1-3-1-2 Each independently represents a C1-C6 alkyl group, a C1-C6 alkoxy group or -(C=O)-R a .
[0092] In one scheme, R a C6~C 14 Aryl.
[0093] In one scheme, each R 1-3-2 are each independently halogen.
[0094] In one scheme, each R 1-3-3 Each independently is a C1-C6 alkyl group or is replaced by one or more R 1-3-3-1 Replacement C6~C 14 Aryl.
[0095] In one scheme, each R 1-3-3-1 Each is independently cyano or C1-C6 alkoxy.
[0096] In one scheme, R 1a -Si(R 1a-1 )3.
[0097] In one scheme, R 1b and R 1c Each independently is C6-C 14 Aryl.
[0098] In one scheme, R 1d and R 1e Each is independently a C1-C6 alkyl group.
[0099] In one scheme, R 2 is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C6-C 14 Aryl, C3~C 12 Cycloalkyl, C3~C 12 Heterocycloalkyl, C3~C 12 Cycloalkenyl, with one or more R 2-1 Replacement C6~C 14 Aryl, one or more R 2-2 Replacement C5~C 12 Heteroaryl, C1-C6 alkylthio, -OR 2-3 or one or more R 2-4 Replacement C3~C 12 Heterocycloalkyl.
[0100] In one scheme, each R 2-1 and R 2-2 Each is independently -(C=O)-O-C1~C6 alkyl, C1~C6 alkyl or halogen.
[0101] In one scheme, R 2-3 For one or more R 2-3-1 Substituted C1-C6 alkyl.
[0102] In one scheme, each R 2-3-1 Each independently is C6~C 14 Aryl.
[0103] In one embodiment, in the compound represented by formula L, For example
[0104] In one embodiment, in ring B, For example
[0105] In one scheme, R 4 wherein the C1-C6 alkyl groups are each independently methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl, for example, isopropyl or tert-butyl.
[0106] In one embodiment, in T, the halogen is F, Cl, Br or I, such as Cl or Br.
[0107] In one embodiment, in L1 and L2, the C1-C6 alkylene groups are each independently methylene, ethylene, n-propylene, isopropylene, n-butylene, isobutylene, tert-butylene or n-pentylene, for example, methylene, ethylene, n-propylene, n-butylene or n-pentylene.
[0108] In one scheme, R 1 In the above, the halogen is fluorine, chlorine, bromine or iodine, for example chlorine.
[0109] In one scheme, R 1 In the above, C6~C 14 Aryl is phenyl or naphthyl, for example phenyl.
[0110] In one scheme, R 1 In the above, C5~C 12 The heteroaryl group is a C5-C6 heteroaryl group. In the C5-C6 heteroaryl group, the heteroatom is preferably N and / or O, and the number of the heteroatoms is preferably 1 or 2.
[0111] In one scheme, R 1 In the above, C3~C 12 The cycloalkyl group is a C3-C6 cycloalkyl group, for example, a cyclohexyl group.
[0112] In one scheme, R 1 In the above, C3~C 12 Heterocycloalkyl and one or more R 1-4 Replacement C3~C 12 C3~C 12The heterocycloalkyl groups are each independently C3-C6 heterocycloalkyl groups, wherein the heteroatoms are preferably N and / or O, and the number of heteroatoms is preferably 1 or 2. The C3-C6 heterocycloalkyl groups are further preferably
[0113] In one scheme, R 1 In the above, the one or more R 1b Substituted C6~C 14 C6~C 14 Aryl is phenyl or naphthyl, for example phenyl.
[0114] In one scheme, R 1 In the above, the one or more R 1c Substituted C5~C 12 C5~C 12 The heteroaryl group is a C5-C6 heteroaryl group. In the C5-C6 heteroaryl group, the heteroatom is preferably N and / or O, and the number of the heteroatoms is preferably 1 or 2.
[0115] In one scheme, R 1-4 In the embodiment, the amino protecting group is tert-butyloxycarbonyl, benzyloxycarbonyl, 2-biphenyl-2-propyloxycarbonyl, p-toluenesulfonyl, formyl or trifluoroacetyl, for example, tert-butyloxycarbonyl.
[0116] In one scheme, R 1-1 and R 1-2 wherein the C1-C6 alkyl group and one or more R 1-1-1 The C1-C6 alkyl groups in the substituted C1-C6 alkyl groups are each independently methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl, for example, methyl.
[0117] In one scheme, R 1-1-1 In the above, C6~C 14 Aryl is phenyl or naphthyl, for example phenyl.
[0118] In one scheme, R 1-1-1 In the above, C5~C 12 The heteroaryl group is a C5-C6 heteroaryl group. In the C5-C6 heteroaryl group, the heteroatom is preferably N and / or O, and the number of the heteroatoms is preferably 1 or 2.
[0119] In one scheme, each R 1-1-2 wherein the C1-C6 alkyl groups are each independently methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl, for example, methyl or tert-butyl.
[0120] In one scheme, R 1-3 and R 1-1-3wherein the C1-C6 alkyl group and one or more R 1-3-1 The C1-C6 alkyl in the substituted C1-C6 alkyl is independently methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl, for example methyl.
[0121] In one scheme, R 1-3 and R 1-1-3 In the above, the C1-C6 alkoxy group is methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy or tert-butoxy, such as ethoxy.
[0122] In one scheme, R 1-3 and R 1-1-3 In the above, the C1-C6 alkylthio group is methylthio, ethylthio, n-propylthio, isopropylthio, n-butylthio, isobutylthio or tert-butylthio.
[0123] In one scheme, R 1-3 and R 1-1-3 In the above, C6~C 14 Aryl and one or more R 1-3-2 Replacement C6~C 14 C6~C 14 Each aryl group is independently phenyl or naphthyl, for example phenyl.
[0124] In one scheme, R 1-3 and R 1-1-3 In the above, C5~C 12 Heteroaryl and one or more R 1-3-3 Replacement C5~C 12 C5~C 12 The heteroaryl groups are each independently C5-C6 heteroaryl groups, wherein the heteroatom in the C5-C6 heteroaryl groups is preferably N and / or S, and the number of heteroatoms is preferably 1 or 2. The C5-C6 heteroaryl groups are further preferably
[0125] In one scheme, each R 1-3-1 In the above, C6~C 14 Aryl and one or more R 1-3-1-1 Replacement C6~C 14 C6~C 14 The aryl groups are each independently phenyl or naphthyl.
[0126] In one scheme, each R 1-3-1 In the above, C5~C 12 heteroaryl and one or more R 1-3-1-2 Replacement C5~C 12 C5~C 12 The heteroaryl groups are each independently C5 to C10 Heteroaryl, the C5~C 10 In the heteroaryl group, the heteroatom is preferably N, the number of heteroatoms is preferably 1, and the C5 to C 10 The heteroaryl group is more preferably
[0127] In one scheme, each R 1-3-1-1 and R 1-3-1-2 In the above, the C1-C6 alkyl group is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl, for example, methyl.
[0128] In one scheme, each R 1-3-1-1 and R 1-3-1-2 In the above, the C1-C6 alkoxy group is methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy or tert-butoxy, for example, methoxy.
[0129] In one scheme, each R 1-3-1-1 and R 1-3-1-2 In the above, the C1-C6 alkylthio group is methylthio, ethylthio, n-propylthio, isopropylthio, n-butylthio, isobutylthio or tert-butylthio.
[0130] In one scheme, R a In the above, C6~C 14 Aryl and C6~C 14 C6~C 14 Each aryl group is independently phenyl or naphthyl, for example phenyl.
[0131] In one scheme, R a In the above, C5~C 12 Heteroaryl and C5~C 12 C5~C 12 The heteroaryl groups are each independently a C5-C6 heteroaryl group. In the C5-C6 heteroaryl group, the heteroatom is preferably N and / or O, and the number of heteroatoms is preferably 1 or 2.
[0132] In one scheme, R a wherein the C6-C 14 Aryl and C5~C 12 Halogen in heteroaryl is each independently fluorine, chlorine, bromine or iodine, for example chlorine.
[0133] In one scheme, each R 1-3-2 In the above, the halogen is fluorine, chlorine, bromine or iodine, for example chlorine.
[0134] In one scheme, each R 1-3-3In the above, the C1-C6 alkyl group is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl, for example, methyl.
[0135] In one scheme, each R 1-3-3 In the above, C6~C 14 Aryl and one or more R 1-3-3-1 Replacement C6~C 14 C6~C 14 Each aryl group is independently phenyl or naphthyl, for example phenyl.
[0136] In one scheme, each R 1-3-3 In the above, C5~C 12 heteroaryl and one or more R 1-3-3-2 Replacement C5~C 12 C5~C 12 The heteroaryl groups are each independently a C5-C6 heteroaryl group. In the C5-C6 heteroaryl group, the heteroatom is preferably N and / or O, and the number of heteroatoms is preferably 1 or 2.
[0137] In one scheme, each R 1-3-3-1 and R 1-3-3-2 wherein the halogen is fluorine, chlorine, bromine or iodine.
[0138] In one scheme, each R 1-3-3-1 and R 1-3-3-2 In the above, the C1-C6 alkylthio group is methylthio, ethylthio, n-propylthio, isopropylthio, n-butylthio, isobutylthio or tert-butylthio.
[0139] In one scheme, each R 1-3-3-1 and R 1-3-3-2 In the above, the C1-C6 alkoxy group is methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy or tert-butoxy, for example tert-butoxy.
[0140] In one scheme, R 1a In the above, the C1-C6 alkyl group is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl.
[0141] In one scheme, R 1a-1 In the above, the C1-C6 alkyl group is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl, for example, ethyl.
[0142] In one scheme, R 1b and R 1c In the above, C6~C 14 Each aryl group is independently phenyl or naphthyl, for example phenyl.
[0143] In one scheme, R 1band R 1c In the above, C5~C 12 The heteroaryl groups are each independently a C5-C6 heteroaryl group. In the C5-C6 heteroaryl group, the heteroatom is preferably N and / or O, and the number of heteroatoms is preferably 1 or 2.
[0144] In one scheme, R 1d and R 1e In the above, the C1-C6 alkyl group is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl, for example, ethyl.
[0145] In one scheme, R 2 In the above, the halogen is fluorine, chlorine, bromine or iodine, for example chlorine.
[0146] In one scheme, R 2 In the above, the C1-C6 alkyl group is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl, for example, methyl or isopropyl.
[0147] In one scheme, R 2 In the above, the C2-C6 alkenyl group is vinyl, n-propenyl, isopropenyl, n-butenyl or 3-methyl-1-propenyl, such as vinyl.
[0148] In one scheme, R 2 In the above, C6~C 14 Aryl and one or more R 2-1 Replacement C6~C 14 C6~C 14 Each aryl group is independently phenyl or naphthyl, for example phenyl.
[0149] In one scheme, R 2 In the above, C5~C 12 heteroaryl and one or more R 2-2 Replacement C5~C 12 C5~C 12 The heteroaryl groups are each independently C5-C6 heteroaryl groups, in which the heteroatom is preferably O, and the number of heteroatoms is preferably 1 or 2. The C5-C6 heteroaryl groups are further preferably
[0150] In one scheme, R 2 In the above, C3~C 12 The cycloalkyl group is a C3-C6 cycloalkyl group, for example, a cyclopropyl group, a cyclopentyl group or a cyclohexyl group.
[0151] In one scheme, R 2 In the above, C3~C 12 Heterocycloalkyl and one or more R 2-4Replacement C3~C 12 C3~C 12 The heterocycloalkyl groups are each independently C3-C6 heterocycloalkyl groups, wherein the heteroatoms are preferably N and / or O, and the number of heteroatoms is preferably 1. The C3-C6 heterocycloalkyl groups are further preferably
[0152] In one scheme, R 2 In the above, C3~C 12 The cycloalkenyl group is a C3-C6 cycloalkenyl group, for example, the C3-C6 cycloalkenyl group is a cyclopropenyl group, a cyclobutenyl group, a cyclopentenyl group or a cyclohexene group, the number of unsaturated carbon-carbon double bonds in the C3-C6 cycloalkenyl group is preferably 1 or 2, and the C3-C6 cycloalkenyl group is further preferably
[0153] In one scheme, R 2 In the above, the C1-C6 alkoxy group is methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy or tert-butoxy.
[0154] In one scheme, R 2 In the above, the C1-C6 alkylthio group is methylthio, ethylthio, n-propylthio, isopropylthio, n-butylthio, isobutylthio or tert-butylthio, for example, methylthio.
[0155] In one scheme, each R 2-4 In the embodiment, the amino protecting group is tert-butyloxycarbonyl, benzyloxycarbonyl, 2-biphenyl-2-propyloxycarbonyl, p-toluenesulfonyl, formyl or trifluoroacetyl, for example, tert-butyloxycarbonyl.
[0156] In one scheme, each R 2-1 and R 2-2 In the -(C=O)-O-C1~C6 alkyl group and the C1~C6 alkyl group, the C1~C6 alkyl group is independently methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl, such as methyl or ethyl.
[0157] In one scheme, each R 2-1 and R 2-2 In the above, the halogen is fluorine, chlorine, bromine or iodine, for example chlorine, bromine or iodine.
[0158] In one scheme, R 2-3 wherein the C1-C6 alkyl group and one or more R 2-3-1 The C1-C6 alkyl group in the substituted C1-C6 alkyl group is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl, for example, methyl.
[0159] In one scheme, each R 2-3-1 In the above, C6~C14 Aryl is phenyl or naphthyl, for example phenyl.
[0160] In one scheme, each R 2-3-1 In the above, C5~C 12 The heteroaryl group is a C5-C6 heteroaryl group. In the C5-C6 heteroaryl group, the heteroatom is preferably O and / or N, and the number of the heteroatoms is preferably 1 or 2.
[0161] In one embodiment, in the preparation method of the compound represented by formula I,
[0162]
[0163] R 3 H or
[0164]
[0165] R 4 is a C1-C6 alkyl group;
[0166] The nickel salt is Ni(T)2 or a DME complex of Ni(T)2;
[0167] The nickel complex is a COD complex of nickel;
[0168] T is a halogen;
[0169] X is I or Br;
[0170] Y is fluorenyl;
[0171] L1 and L2 are each independently a C1-C6 alkylene group or a chemical bond;
[0172] R 1 Halogen, cyano, C6~C 14 Aryl, C3~C 12 Cycloalkyl, C3~C 12 Heterocycloalkyl, with one or more R 1-4 Replacement C3~C 12 Heterocycloalkyl, -NHR 1-1 、-OR 1-2 , -(C=O)-R 1-3 , or one or more R 1b Substituted C6~C 14 Aryl;
[0173] R 1-4 is an amino protecting group;
[0174] R 1-1 and R 1-2 Each independently is one or more R1-1-1 Substituted C1-C6 alkyl, -Si(R 1-1-2 )3 or -(C=O)-R 1-1-3 ;
[0175] Each R 1-1-1 Each independently is C6~C 14 Aryl;
[0176] Each R 1-1-2 Each is independently a C1-C6 alkyl group;
[0177] R 1-3 and R 1-1-3 Each independently is one or more R 1-3-1 Substituted C1-C6 alkyl, C1-C6 alkoxy, one or more R 1-3-2 Replacement C6~C 14 Aryl, one or more R 1-3-3 Replacement C5~C 12 Heteroaryl or
[0178] Each R 1-3-1 Each independently is one or more R 1-3-1-2 Replacement C5~C 12 heteroaryl;
[0179] Each R 1-3-1-2 Each independently represents a C1-C6 alkyl group, a C1-C6 alkoxy group or -(C=O)-R a ;
[0180] R a C6~C 14 Aryl;
[0181] Each R 1-3-2 are each independently a halogen;
[0182] Each R 1-3-3 Each independently is a C1-C6 alkyl group or is replaced by one or more R 1-3-3-1 Replacement C6~C 14 Aryl;
[0183] Each R 1-3-3-1 Each is independently cyano or C1-C6 alkoxy;
[0184] R 1a -Si(R 1a-1 )3, each R 1a-1 Each is independently a C1-C6 alkyl group;
[0185] R 1b C6-C 14 Aryl;
[0186] R 1d and R 1e Each is independently a C1-C6 alkyl group;
[0187] R 2 is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C6-C 14 Aryl, C3~C 12 Cycloalkyl, C3~C 12 Heterocycloalkyl, C3~C 12 Cycloalkenyl, with one or more R 2-1 Replacement C6~C 14 Aryl, one or more R 2-2 Replacement C5~C 12 Heteroaryl, C1-C6 alkylthio, -OR 2-3 or one or more R 2-4 Replacement C3~C 12 Heterocycloalkyl;
[0188] R 2-4 is an amino protecting group;
[0189] Each R 2-1 and R 2-2 Each is independently -(C=O)-O-C1~C6 alkyl, C1~C6 alkyl or halogen;
[0190] R 2-3 For one or more R 2-3-1 Substituted C1-C6 alkyl;
[0191] Each R 2-3-1 Each independently is C6~C 14 Aryl;
[0192] Each of the C5~C 12 Heteroaryl and C3~C 12 In the heterocycloalkyl group, the heteroatom is selected from one or more of N, O and S, and the number of the heteroatoms is 1, 2 or 3.
[0193] In one embodiment, in the preparation method of the compound of formula I, in the solvent, under the action of MHMDS, the nickel salt and the ligand, the compound of formula II and the compound of formula III are coupled to obtain the compound of formula I;
[0194]
[0195] R 3 is H;
[0196]
[0197] R 4 is a C1-C6 alkyl group;
[0198] M is Li;
[0199] The nickel salt is a DME complex of Ni(T)2;
[0200] T is a halogen;
[0201] X is I or Br;
[0202] Y is fluorenyl;
[0203] L1 and L2 are each independently a C1-C6 alkylene group or a chemical bond;
[0204] R 1 Halogen, cyano, C6~C 14 Aryl, C3~C 12 Cycloalkyl, C3~C 12 Heterocycloalkyl, with one or more R 1-4 Replacement C3~C 12 Heterocycloalkyl, -NHR 1-1 、-OR 1-2 , -(C=O)-R 1-3 , or one or more R 1b Substituted C6~C 14 Aryl;
[0205] R 1-4 is an amino protecting group;
[0206] R 1-1 and R 1-2 Each independently is one or more R 1-1-1 Substituted C1-C6 alkyl, -Si(R 1-1-2 )3 or -(C=O)-R 1-1-3 ;
[0207] Each R 1-1-1 Each independently is C6~C 14 Aryl;
[0208] Each R 1-1-2 Each is independently a C1-C6 alkyl group;
[0209] R 1-3 and R 1-1-3 Each independently is one or more R 1-3-1 Substituted C1-C6 alkyl, C1-C6 alkoxy, one or more R 1-3-2 Replacement C6~C 14 Aryl, one or more R 1-3-3 Replacement C5~C12 Heteroaryl or
[0210] Each R 1-3-1 Each independently is one or more R 1-3-1-2 Replacement C5~C 12 heteroaryl;
[0211] Each R 1-3-1-2 Each independently represents a C1-C6 alkyl group, a C1-C6 alkoxy group or -(C=O)-R a ;
[0212] R a C6~C 14 Aryl;
[0213] Each R 1-3-2 are each independently a halogen;
[0214] Each R 1-3-3 Each independently is a C1-C6 alkyl group or is replaced by one or more R 1-3-3-1 Replacement C6~C 14 Aryl;
[0215] Each R 1-3-3-1 Each is independently cyano or C1-C6 alkoxy;
[0216] R 1a -Si(R 1a-1 )3, each R 1a-1 Each is independently a C1-C6 alkyl group;
[0217] R 1b C6-C 14 Aryl;
[0218] R 1d and R 1e Each is independently a C1-C6 alkyl group;
[0219] R 2 is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C6-C 14 Aryl, C3~C 12 Cycloalkyl, C3~C 12 Heterocycloalkyl, C3~C 12 Cycloalkenyl, with one or more R 2-1 Replacement C6~C 14 Aryl, one or more R 2-2 Replacement C5~C 12 Heteroaryl, C1-C6 alkylthio, -OR 2-3 or one or more R 2-4 Replacement C3~C 12Heterocycloalkyl;
[0220] R 2-4 is an amino protecting group;
[0221] Each R 2-1 and R 2-2 Each is independently -(C=O)-O-C1~C6 alkyl, C1~C6 alkyl or halogen;
[0222] R 2-3 For one or more R 2-3-1 Substituted C1-C6 alkyl;
[0223] Each R 2-3-1 Each independently is C6~C 14 Aryl;
[0224] Each of the C5~C 12 Heteroaryl and C3~C 12 In the heterocycloalkyl group, the heteroatom is selected from one or more of N, O and S, and the number of the heteroatoms is 1, 2 or 3.
[0225] In one embodiment, in the preparation method of the compound represented by formula I,
[0226]
[0227] R 3 H or
[0228]
[0229] R 4 is H or C1-C6 alkyl;
[0230] The nickel salt is Ni(T)2 or a DME complex of Ni(T)2;
[0231] The nickel complex is a COD complex of nickel;
[0232] T is a halogen;
[0233] X is I or Br;
[0234] Y is fluorenyl;
[0235] L1 and L2 are each independently a C1-C6 alkylene group or a chemical bond;
[0236] R 1 Halogen, cyano, C6~C 14 Aryl, C3~C 12 Cycloalkyl, C3~C 12 Heterocycloalkyl, with one or more R 1-4 Replacement C3~C12 Heterocycloalkyl, -NHR 1-1 、-OR 1-2 or -(C=O)-R 1-3 ;
[0237] R 1-4 is an amino protecting group;
[0238] R 1-1 and R 1-2 Each independently is one or more R 1-1-1 Substituted C1-C6 alkyl, -Si(R 1-1-2 )3 or -(C=O)-R 1-1-3 ;
[0239] Each R 1-1-1 Each independently is C6~C 14 Aryl;
[0240] Each R 1-1-2 Each is independently a C1-C6 alkyl group;
[0241] R 1-3 and R 1-1-3 Each independently is one or more R 1-3-1 Substituted C1-C6 alkyl, C1-C6 alkoxy, one or more R 1-3-2 Replacement C6~C 14 Aryl or one or more R 1-3-3 Replacement C5~C 12 heteroaryl;
[0242] Each R 1-3-1 Each independently is one or more R 1-3-1-2 Replacement C5~C 12 heteroaryl;
[0243] Each R 1-3-1-2 Each independently represents a C1-C6 alkyl group, a C1-C6 alkoxy group or -(C=O)-R a ;
[0244] R a C6~C 14 Aryl;
[0245] Each R 1-3-2 are each independently a halogen;
[0246] Each R 1-3-3 Each independently is a C1-C6 alkyl group or is replaced by one or more R 1-3-3-1 Replacement C6~C 14 Aryl;
[0247] Each R 1-3-3-1Each is independently cyano or C1-C6 alkoxy;
[0248] R 2 is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C6-C 14 Aryl, C3~C 12 Cycloalkyl, C3~C 12 Heterocycloalkyl, C3~C 12 Cycloalkenyl, with one or more R 2-1 Replacement C6~C 14 Aryl, one or more R 2-2 Replacement C5~C 12 Heteroaryl, C1-C6 alkylthio, -OR 2-3 or one or more R 2-4 Replacement C3~C 12 Heterocycloalkyl;
[0249] R 2-4 is an amino protecting group;
[0250] Each R 2-1 and R 2-2 Each is independently -(C=O)-O-C1~C6 alkyl, C1~C6 alkyl or halogen;
[0251] R 2-3 For one or more R 2-3-1 Substituted C1-C6 alkyl;
[0252] Each R 2-3-1 Each independently is C6~C 14 Aryl;
[0253] Each of the C5~C 12 Heteroaryl and C3~C 12 In the heterocycloalkyl group, the heteroatom is selected from one or more of N, O and S, and the number of the heteroatoms is 1, 2 or 3.
[0254] In one embodiment, the compound represented by formula L is For example
[0255] In one solution, Y is
[0256] In one embodiment, L1 is methylene, n-butylene, n-propylene, n-pentylene or a chemical bond.
[0257] In one embodiment, L2 is methylene, ethylene, a chemical bond or n-propylene.
[0258] In one scheme, R 1 is halogen (Cl), cyano, phenyl, cyclohexane,
[0259] In one scheme, R 1 is halogen (e.g. Cl), cyano, phenyl, cyclohexyl,
[0260] In one scheme, R 2 is hydrogen, phenyl, Isopropyl, Vinyl, methylthio, Methyl, or
[0261] In one embodiment, the compound represented by formula L is any of the following compounds:
[0262]
[0263] In one embodiment, the nickel complex is Ni(COD)2.
[0264] In one embodiment, in the nickel salt, the DME complex of Ni(T)2 is NiCl2·DME or NiBr2·DME.
[0265] In one embodiment, in the nickel salt, Ni(T)2 is NiCl2.
[0266] In one embodiment, the compound represented by formula II is any of the following compounds:
[0267]
[0268]
[0269] In one embodiment, the compound represented by formula II is any of the following compounds:
[0270] In one embodiment, the compound represented by formula III is any of the following compounds:
[0271] In one embodiment, the compound represented by formula III is any of the following compounds:
[0272]
[0273] In one embodiment, the compound represented by formula I is any of the following compounds:
[0274]
[0275]
[0276] In one embodiment, the coupling reaction is carried out in a protective gas.
[0277] In one embodiment, in the coupling reaction, the protective gas is a conventional protective gas for such reactions in the art, such as argon.
[0278] In one embodiment, in the coupling reaction, the solvent is a conventional solvent for such reactions in the art, such as an ether solvent, preferably THF.
[0279] In one embodiment, in the coupling reaction, the ratio of the amount (mmol) to the volume (mL) of the compound represented by Formula III and the solvent is conventional in the art, such as 0.2: (0.5-10) mmol / mL, preferably 0.1: 1 mmol / mL.
[0280] In one embodiment, in the coupling reaction, the molar ratio (molar ratio) of the MHMDS (eg, LiHMDS) and the compound represented by formula III is conventional in the art, for example (0.5-2):1, preferably 1.5:1.
[0281] In one embodiment, in the coupling reaction, the molar ratio (molar ratio) of the nickel salt or nickel complex to the compound represented by formula III is conventional in the art, for example (1-20):100, preferably 1:10.
[0282] In one embodiment, in the coupling reaction, the molar ratio (molar ratio) of the compound represented by formula L and the compound represented by formula III is conventional in the art, for example (1-20):100, preferably 3:25.
[0283] In one embodiment, in the coupling reaction, the molar ratio (molar ratio) of the compound represented by formula II and the compound represented by formula III is conventional in the art, for example (0.5-2):1, preferably 1.5:1.
[0284] In one embodiment, the coupling reaction temperature is a conventional temperature for such reactions in the art, such as room temperature; the room temperature refers to 0°C to 30°C; preferably, the MHMDS (eg, LiHMDS) is added to the reaction system at 0°C.
[0285] In one embodiment, the raw materials of the coupling reaction are the solvent, the MHMDS, the nickel salt or nickel complex, the ligand (the compound represented by formula L), the compound represented by formula II and the compound represented by formula III; for example, the raw materials of the coupling reaction are tetrahydrofuran, LiHMDS, NiCl2 DME complex (NiCl2·DME), The compound represented by formula II and the compound represented by formula III.
[0286] In the reaction, the progress of the coupling reaction can be detected by conventional monitoring methods for such reactions in the art (e.g., HPLC, LCMS), and the reaction endpoint is generally taken as the disappearance or no-reaction of the compound represented by formula II. The reaction time can be the conventional reaction time for such reactions in the art, for example, 2 to 12 hours.
[0287] In one embodiment, the coupling reaction comprises the following steps: in a protective gas, mixing the nickel salt or nickel complex with a mixture of the compound represented by the formula L and the compound represented by the formula II, adding part of the solvent (e.g., 1 / 2 of the solvent) to obtain a mixture A, mixing the LiHMDS with the mixture A at 0°C to obtain a mixture B, mixing the remaining part of the solvent (e.g., 1 / 2 of the solvent) and the compound represented by the formula III with the mixture B, and performing the coupling reaction at room temperature.
[0288] The present invention provides a method for preparing a compound represented by formula I-1, comprising the following steps:
[0289] (1) preparing the compound of formula I according to the preparation method of the compound of formula I above;
[0290] (2) Under the action of a reducing agent, the compound represented by formula I undergoes a reduction reaction to obtain a compound represented by formula I-1;
[0291]
[0292] Among them, R 1 , R 2 , L1, L2 and Y are as described in any one of the present invention.
[0293] In one embodiment, the compound represented by formula I-1 is any of the following compounds:
[0294]
[0295]
[0296] In one embodiment, in the reduction reaction, the reducing agent is a conventional reducing agent for such reactions in the art, such as NaBH4.
[0297] In one embodiment, in the reduction reaction, the molar ratio (molar ratio) of the reducing agent to the compound represented by formula III is conventional in the art, for example (1-10):1, preferably 3:1.
[0298] In one embodiment, in the reduction reaction, the solvent of the reduction reaction is a conventional solvent for such reactions in the art, such as a halogenated hydrocarbon solvent, preferably DCM, or a mixed solvent of a halogenated hydrocarbon and an ether solvent. It is further preferred that after the coupling reaction is completed, a halogenated hydrocarbon solvent (such as dichloromethane) is added for dilution.
[0299] In one embodiment, the reduction reaction is directly performed after the coupling reaction is completed (without post-treatment).
[0300] In one embodiment, the reduction reaction further comprises an auxiliary agent, preferably a Bronsted acid, such as acetic acid.
[0301] In one embodiment, in the reduction reaction, the ratio (molar ratio) of the amount of the auxiliary agent to the compound represented by formula III is conventional in the art, for example (1-40):1, preferably 20:1.
[0302] In one embodiment, the raw materials for the reduction reaction are the reducing reagent, the solvent for the reduction reaction, the auxiliary agent and the compound shown in formula I. For example, the raw materials for the reduction reaction are NaBH4, DCM, acetic acid and the compound shown in formula I.
[0303] In a certain scheme, the reduction reaction comprises the following steps: after the coupling reaction is completed, a reaction solution is obtained, the solvent of the reduction reaction, the reducing reagent and the reaction solution are mixed, an auxiliary agent is added (for example, glacial acetic acid is added dropwise and stirred for 1 hour) to carry out a reduction reaction, after the reaction is completed, a base is added (for example, 10% sodium hydroxide solution is stirred for 20 minutes), extraction (for example, extraction with DCM), drying (for example, drying with anhydrous sodium sulfate), filtering, concentrating, and purification (for example, column chromatography) to obtain the compound represented by formula I-1.
[0304] Terminology explanation:
[0305] Unless otherwise stated, the technical terms used in the specification and claims have the following meanings.
[0306] When a numerical range is listed, it is intended to include each value and sub-range within the stated range. For example, "C1-C6" includes C1, C2, C3, C4, C5, C6, C1-C6, C1-C5, C1-C4, C1-C3, C1-C2, C2-C6, C2-C5, C2-C4, C2-C3, C3-C6, C3-C5, C3-C4, C4-C6, C4-C5, and C5-C6 alkyl.
[0307] The term "halogen" refers to fluorine, chlorine, bromine or iodine.
[0308] The term "alkyl" refers to a straight or branched chain alkyl group having a specified number of carbon atoms (e.g., C1 to C6). Alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, isobutyl, sec-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, and the like.
[0309] The term "alkylene" means a saturated divalent hydrocarbon group derived from a saturated straight or branched hydrocarbon group by removing two hydrogen atoms; that is, one hydrogen in an alkyl group is replaced, and the definition of alkyl is as described above, for example, C 1-6 Alkylene.
[0310] The term "alkoxy" refers to a group R X -O-, where R X is an alkyl group as defined above.
[0311] The term "alkylthio" refers to a group R Y -S-, where R Y is an alkyl group as defined above.
[0312] The term "cycloalkyl" refers to a cycloalkyl radical having a specified number of carbon atoms (e.g., C3 to C 12 ) is a saturated monocyclic cyclic group consisting of only carbon atoms. Cycloalkyl includes, but is not limited to, cyclopropane, cyclobutane, cyclopentane, cyclohexane, etc.
[0313] The term "heterocycloalkyl" refers to a cyclic group having a specified number of ring atoms (e.g., 3 to 12 members), a specified number of heteroatoms (e.g., 1, 2, or 3), and a specified heteroatom type (one or more of N, O, and S), which is a monocyclic, bridged, or spirocyclic ring, and each ring is saturated. A bridged ring refers to a polycyclic ring that shares two or more atoms between monocyclic rings. A spirocyclic ring refers to a polycyclic ring that shares one atom between monocyclic rings. Heterocycloalkyl includes, but is not limited to, azetidinyl, tetrahydropyrrolyl, tetrahydrofuranyl, morpholinyl, piperidinyl, and the like.
[0314] The term "aryl" refers to a group having a specified number of carbon atoms (e.g., C6 to C 14 ) and is composed only of carbon atoms, which is monocyclic or polycyclic, and at least one ring is aromatic (in accordance with Huckel's rule). The aryl group is connected to other fragments in the molecule through an aromatic ring or a non-aromatic ring. The aryl group includes, but is not limited to, phenyl, naphthyl, etc.
[0315] The term "heteroaryl" refers to a cyclic group having a specified number of ring atoms (e.g., 5 to 12 members), a specified number of heteroatoms (e.g., 1, 2, or 3), a specified type of heteroatoms (one or more of N, O, and S), which is monocyclic or polycyclic, and at least one ring is aromatic (in accordance with Huckel's rule). The heteroaryl group is connected to other fragments in the molecule through an aromatic ring or a non-aromatic ring. Heteroaryl includes, but is not limited to, furanyl, pyrrolyl, thienyl, pyrazolyl, imidazolyl, oxazolyl, thiazolyl, pyridyl, pyrimidinyl, indolyl, and the like.
[0316] The "-" at the end of a group means that the group is connected to other fragments in the molecule through this site. For example, CH3-C(=O)- refers to acetyl.
[0317] In the structure fragment It means that the structural fragment is connected to other fragments in the molecule through this site. For example, It refers to cyclohexyl.
[0318] The term "plurality" refers to 2, 3, 4 or 5.
[0319] "Alkenyl" refers to a straight or branched chain hydrocarbon group containing one or more carbon-carbon double bonds (eg, 1, 2, or 3 carbon-carbon double bonds).
[0320] The term "C3-C n "Cycloalkyl" refers to a non-aromatic cyclic hydrocarbon group having 3 to n ring carbon atoms and zero heteroatoms, n being an integer greater than 3. Exemplary cycloalkyl groups include, but are not limited to, cyclopropane, cyclopropene, cyclobutane, cyclobutenyl, cyclopentane, cyclopentenyl, cyclohexane, cyclohexenyl, cyclohexadienyl, cycloheptane, cycloheptenyl, cycloheptadienyl, cycloheptatrienyl, and the like.
[0321] In the present invention, the term "cycloalkenyl" refers to a cyclic, partially unsaturated hydrocarbon group having a specified number of carbon atoms (e.g., 3 to 12 members) and having one or more (e.g., 1, 2 or 3) carbon-carbon sp 2 Double bond, it is a single ring, not aromatic. The cycloalkenyl group is attached to the rest of the molecule through a carbon atom.
[0322] When any variable (such as the group R 1-1 ) appears multiple times in the definition of a compound, their definitions are independent of each other and do not affect each other. 2-1 Substituted C6~C 14 Aryl refers to C6~C 14 The aromatic group may be 1, 2 or 3 R 2-1 Replacement, 3 R's 2-1 The definitions are independent of each other and do not affect each other.
[0323] LiHMDS: lithium bis(trimethylsilyl)amide.
[0324] NaHMDS: sodium bis(trimethylsilyl)amide.
[0325] KHMDS: potassium bis(trimethylsilyl)amide.
[0326] LDA: lithium diisopropylamide.
[0327] DCC: 1,3-dicyclohexylcarbodiimide.
[0328] Flu is fluorenyl.
[0329] On the basis of being in accordance with the common sense in the art, the above-mentioned preferred conditions can be arbitrarily combined to obtain the preferred embodiments of the present invention.
[0330] The reagents and raw materials used in the present invention are commercially available.
[0331] The positive progressive effect of the present invention is that the method provided by the present invention can effectively promote the preparation of difluoroalkylamines by coupling reaction of non-activated difluoroalkyl halides, has good reaction applicability, high yield, and has a wide range of application scenarios. DETAILED DESCRIPTION
[0332] The present invention is further described below by way of examples, but the present invention is not limited to the scope of the examples. The experimental methods in the following examples without specifying specific conditions are carried out according to conventional methods and conditions, or selected according to the product specifications.
[0333] Example 1 Investigation of ligands
[0334] Add ligand L (12 mol%) and 16a (0.3 mmol, 1.5 equiv) in the following table to a 25 mL sealed tube, take the sealed tube into a glove box and add NiCl2·DME (4.4 mg, 10 mol%). Take the sealed tube out of the glove box and connect it to a double row, replace the gas three times, add tetrahydrofuran (1 mL) under argon atmosphere, and pre-stir for 20 minutes. Then, add LiHMDS (0.3 mL, 1.0 M THF solution, 1.5 equiv) dropwise to the sealed tube at 0°C. After the addition is complete, add 17a (0.2 mmol, 1.0 equiv) and rinse with tetrahydrofuran (1 mL). Return to room temperature and react for 12 hours. Before post-reaction treatment, NMR 19 The results of the nuclear magnetic yield determination of F (fluorobenzene as internal standard) are shown in Table 1.
[0335] Table 1 Ligand investigation
[0336]
[0337] b Fluorobenzene was used as internal standard. 19 The yield was determined by F NMR.
[0338] As shown in the table above, the pyridine oxazole ligand L7 can obtain the target product 18a' with a fluorine spectrum yield of 70%, and no other regioselective products are observed (item 1). The use of tert-butyl substituted pyridine oxazole ligand L22 can further increase the yield to 88% (item 3). At the same time, the chiral bisphosphine ligand L31 and the nitrogen heterocyclic carbene ligand L32 have lower yields (items 7-8).
[0339] Example 2 Other reaction conditions
[0340] Referring to the reaction conditions of Example 1, add ligand L22 (12 mol%) and 16a (0.3 mmol, 1.5 equiv) to a 25 mL sealed tube, take the sealed tube into a glove box and add NiCl2·DME (4.4 mg, 10 mol%). Take the sealed tube out of the glove box and connect it to a double row, replace the gas three times, add tetrahydrofuran (1 mL) under an argon atmosphere, and pre-stir for 20 minutes. Then, at 0°C, add base LiHMDS (0.3 mL, 1.0 M THF solution, 1.5 equiv) dropwise to the sealed tube. After the addition is complete, add 17a (0.2 mmol, 1.0 equiv) and rinse with tetrahydrofuran (1 mL). Return to room temperature and react for the time recorded in the table below. NMR before post-reaction treatment 19 The results of the nuclear magnetic yield determination of F (fluorobenzene as internal standard) are shown in Table 2.
[0341] Table 2 Reaction time
[0342]
[0343] b Fluorobenzene was used as internal standard. 19 Yield determined by F NMR
[0344] The reaction time was investigated (Table 2). As shown in the table above, after 2 minutes of reaction, we can obtain the product with an 80% yield (item 1). After 2 hours of reaction, the yield reached the highest (88%) (item 2). At this time, the raw materials were consumed and the product was relatively stable in the system.
[0345] The L22 and Ni catalysts were investigated, and the results are shown in Table 3
[0346] Project 1: Add ligand L22 (12 mol%) and 16a (0.3 mmol, 1.5 equiv) to a 25 mL sealed tube, take the sealed tube out of the glove box and connect it to the double row, replace the gas three times, add tetrahydrofuran (1 mL) under argon atmosphere, and pre-stir for 20 minutes. Then, at 0°C, add base LiHMDS (0.3 mL, 1.0 M THF solution, 1.5 equiv) dropwise to the sealed tube. After the addition is complete, add 17a (0.3 mmol, 1.0 equiv) and rinse with tetrahydrofuran (1 mL). Return to room temperature and react for 2 hours. Before post-reaction treatment, NMR 19 F was determined by NMR yield (fluorobenzene was used as internal standard).
[0347] Project 2: Add 16a (0.3mmol, 1.5equiv) to a 25mL sealed tube, take the sealed tube into a glove box and add NiCl2·DME (4.4mg, 10mol%). Take the sealed tube out of the glove box and connect it to the double row, replace the gas three times, add tetrahydrofuran (1mL) under argon atmosphere, and pre-stir for 20 minutes. Then, add base LiHMDS (0.3mL, 1.0M THF solution, 1.5equiv) dropwise to the sealed tube at 0°C. After the addition is complete, add 17a (0.2mmol, 1.0equiv) and rinse with tetrahydrofuran (1mL). Return to room temperature and react for 2 hours. Before post-reaction treatment, NMR 19 F determination of NMR yield (fluorobenzene as internal standard)
[0348] Table 3 Catalysts and ligands
[0349]
[0350]
[0351] b Fluorobenzene was used as internal standard. 19 The yield was determined by F NMR.
[0352] As shown in the table above, when no ligand is added, the reaction can still obtain the target product with a yield of 22%. However, when no nickel catalyst is added, the reaction cannot occur. Based on this, the suitable reaction conditions can be obtained as follows: 16a (0.3 mmol, 1.5 equiv), 17 (0.2 mmol, 1.0 equiv), THF (2 mL), NiCl2·DME (10 mol%), L22 (12 mol%), LiHMDS (0.3 mmol, 1.5 equiv).
[0353] It should be noted that since the product imine is easily decomposed during the post-treatment process, we directly added NaBH4 after the reaction to reduce the product imine to amine. Under the above reaction conditions, after reduction post-treatment, we can obtain the coupling product 18a with an isolated yield of 80%.
[0354]
[0355] Example 3 Reaction substrate investigation
[0356] Add L22 (4.9 mg, 12 mol%) and the imine substrate obtained in Example 5 (0.3 mmol, 1.5 equiv) to a 25 mL sealed tube, take the sealed tube into a glove box and add NiCl2·DME (4.4 mg, 10 mol%). Take the sealed tube out of the glove box and connect it to a double row, replace the gas three times, add tetrahydrofuran (1 mL) under an argon atmosphere, and pre-stir for 20 minutes. Then, at 0°C, add LiHMDS (0.3 mL, 1.0 M LiHMDS in THF solution, 1.5 equiv) dropwise to the sealed tube. After the addition is complete, add the difluoroalkyl halide (0.2 mmol, 1.0 equiv) in Example 5 and rinse with tetrahydrofuran (1 mL). Return to room temperature and react for 2 hours. Before post-reaction treatment, NMR 19 F was measured by NMR yield (fluorobenzene was used as internal standard). After the reaction was completed, NaBH 4 (24 mg, 3.0 equiv), dilute with dichloromethane (3 mL), slowly add glacial acetic acid (0.22 mL, 20 equiv) dropwise therein. At this time, the system is turbid and a large number of bubbles emerge. After stirring at room temperature for 1 hour, add 10% sodium hydroxide aqueous solution (1.6 mL) to the system. Continue stirring at room temperature for 20 minutes, and the system gradually becomes clear. The aqueous phase is extracted with dichloromethane (25 mL × 3), the organic phases are combined, dried over anhydrous sodium sulfate, filtered, and concentrated by column chromatography to obtain the target product. The results are shown in Tables 4 and 5.
[0357] Table 4 Substrate investigation
[0358]
[0359] b Difluoroalkyl iodides are electrophilic reagents.
[0360] As shown in the table above, non-activated difluoroalkyl halides 17 react with compound 16a. The reaction is well compatible with common functional groups such as amine, silicon, alkyl chloride and cyano groups (18a-18e). Under strong alkaline conditions, ester groups can also obtain medium to high yields (18f-18g). When the steric hindrance of the difluoroalkyl halide increases, the reaction is not affected (18h-18i). Difluoroalkyl halides derived from complex drug molecules can also effectively participate in the reaction to obtain coupling products in medium yields (18j-18k).
[0361] As shown in Table 5 below, when the alkyl substituent is a small ring, the reaction can proceed well (19a-c), and the method is compatible with cyclopropane and azetidinyl groups. As the ring system becomes larger, the reaction yield decreases (19d-e), which may be due to increased steric hindrance, but the large steric hindrance of 2-aziridine anion does not affect the regioselectivity of the reaction.
[0362] The reaction is well compatible with a range of functional groups, such as ester groups, furan rings, aryl bromides, terminal olefins, thioethers, and benzyloxy groups (19h-m). In particular, the compatibility of terminal olefin functional groups indicates that the difluoroalkyl radicals generated during the reaction can be quickly captured by the nickel metal, thereby reducing the occurrence of side reactions. In addition to alkyl imines, aryl imines can also be coupled under standard conditions, and can even be compatible with aryl iodide functional groups (19n), which is difficult to achieve with existing nickel-catalyzed coupling reactions.
[0363] Table 5 Investigation of substrates
[0364]
[0365] b No ligand L22 was added, c No restore operation is required.
[0366] Example 4
[0367] Add L22 (62 mg, 12 mol%) and 16a (1.13 g, 3.75 mmol, 1.5 equiv) to a 25 mL sealed tube, take the sealed tube into a glove box and add NiCl2·DME (55 mg, 10 mol%). Take the sealed tube out of the glove box and connect it to a double row, replace the gas three times, add tetrahydrofuran (8 mL) under argon atmosphere, and pre-stir for 20 minutes. Then, add LiHMDS (3.75 mL, 1.0 M LiHMDS in THF solution, 1.5 equiv) dropwise to the sealed tube at 0°C. After the addition is complete, add 17a (2.5 mmol, 1.0 equiv) and rinse with tetrahydrofuran (2 mL). Return to room temperature and react for 2 hours. After the reaction is completed, add NaBH4 (234 mg, 3.0 equiv) to the reaction system, dilute with dichloromethane (10 mL), and slowly add glacial acetic acid (2.2 mL, 20 equiv) dropwise. At this time, the system was turbid and a large number of bubbles emerged. After stirring at room temperature for 1 hour, 10% sodium hydroxide aqueous solution (16 mL) was added to the system. Stirring was continued at room temperature for 20 minutes, and the system gradually became clear. The aqueous phase was extracted with dichloromethane (25 mL × 3), and the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated by column chromatography (petroleum ether / ethyl acetate = 10:1) to obtain 960 mg of the target product 18a, with a yield of 82%.
[0368]
[0369] The product obtained by this reaction can be used as a very useful synthetic building block for the synthesis of fluorinated analogs of different biologically active molecules. As shown in Example 8, alkyl imine 16p and difluoroalkyl halide 17l undergo a coupling reaction as shown in the following formula to prepare difluoroalkyl amine compound 19o (yield 90%).
[0370]
[0371] The compound was hydrolyzed and condensed with N-Boc-L-piperidine-2-carboxylic acid to obtain the key intermediate fluorinated analogue 20 of the small molecule protein inhibitor ElteX. Referring to the method in the literature (Martina, MR; Tenori, E.; Bizzarri, M.; Menichetti, S.; Caminati, G.; Procacci, PJ Med. Chem. 2013, 56, 1041-1051.), the fluorinated analogue 21 of ElteX can be synthesized. Due to the introduction of difluoromethylene, the basicity of the amino group is reduced and the acidity of the amide hydrogen is increased, thereby changing the biological activity of ElteX, providing opportunities and possibilities for the discovery of new bioactive molecules for Parkinson's syndrome.
[0372] In addition, referring to the preparation method of Example 6, aryl imine 16q and difluoroalkyl halide 17k can react as shown in the following formula to synthesize compound 19p, which can be used as a key fragment to condense with the corresponding carboxylic acid to quickly obtain the fluorine-containing analogue 22 of the anti-tumor bioactive molecule AZD5363.
[0373]
[0374] It can be seen that the reaction can achieve the synthesis of important difluoroalkylamine building blocks. For example, as shown in Example 8, acetaldehyde imine 16r can react with phenylbromodifluoromethane 9e to obtain difluoroalkylamine 19q. The non-fluorine structure 19q' of compound 19q is widely used in pharmaceutical active molecules, such as the weight loss drug Clobenzorex, the drug lisdexamfetamine for treating ADHD, and the angina prevention and treatment drug prenylamine, all of which contain the same amine structure. We believe that starting from 19q, we can quickly obtain fluorinated analogues of this series of pharmaceutical active molecules, avoiding the need to design a reaction route from scratch, and shortening the time for fluorinated modification of drug molecules. At the same time, the introduction of the difluoromethylene here not only affects the acidity of the NH bond, but also, because it is in the benzyl position, it is beneficial to enhance the metabolic stability of the drug molecule and increase the duration of efficacy.
[0375]
[0376] Example 5 Preparation of reaction substrate Synthesis of synthetic imine:
[0377]
[0378] Synthesis of N-fluorenyl imine: Add to a 25 mL sealed tube that has been dried in advance Molecular sieve (powder) (0.3g / mmol), ventilate three times, add 9-aminofluorene (1.0equiv) and ultra-dry cyclohexane (1mL / mmol) under argon conditions. After stirring for 10 minutes, add the corresponding aldehyde (1.0equiv) and react at room temperature for 2 hours. After the reaction is completed, take the sealed tube into the glove box, filter to remove the molecular sieve, rinse with ultra-dry dichloromethane (1mL / mmol), and concentrate the filtrate to obtain the corresponding imine product. The product needs to be placed in a -20℃ refrigerator for low temperature storage. Referring to the above preparation method, the following compounds are prepared, among which 16k, 16n, and 16o imines are unstable and need to be directly coupled. The reaction scale refers to the amount of the corresponding aldehyde. For example, the reaction scale of 5mmol means adding 5mmol of the corresponding aldehyde for the preparation reaction.
[0379]
[0380] Compound 16b, reaction scale 5 mmol, 1.0 g, white solid, yield 86%. 1 H NMR (400MHz, CDCl3) δ7.71(d,J=6.8Hz,2H),7.50(d,J=6.9Hz,1H),7.36(d,J=7.3Hz,4H),7 .29(d,J=6.7Hz,2H),5.12(s,1H),1.92-1.73(m,1H),1,02-0.90(m,2H),0.87-0.73(m,2H). 13 C NMR (101MHz, CDCl3) δ170.0,144.9,140.8,128.2,127.3,124.9,119.9,73.9,16.7,6.6.MS(ESI):m / z(%)234.1([M+H] + ).HRMS: Calculated value C 17 H 16 N:234.1277; Measured value:234.1273
[0381]
[0382] Compound 16c, reaction scale 5 mmol, 1.65 g, white solid, yield 95%. 1 H NMR (400MHz, CDCl3) δ8.32(d,J=5.4Hz,1H),7.73(d,J=7.5Hz,2H),7.40(t,J=7.3Hz,2H),7.31(d,J= 9.3Hz,4H),5.26(s,1H),4.17(t,J=8.6Hz,2H),4.07(t,J=6.6Hz,2H),3.51-3.38(m,1H),1.44(s,9H) 13 C NMR (101MHz, CDCl3) δ166.2,156.2,144.1,140.9,128.5,127.4,125.0,120.1,79.6,73.8,51.9,33.4,28.3.MS(ESI):m / z(%)349.2([M+H] + ).HRMS: Calculated value C 22 H 25 N2O2:349.1911; Measured value:349.1907
[0383]
[0384] Compound 16d, reaction scale 5 mmol, 1.2 g, white solid, yield 93%. 1H NMR (400MHz, CDCl3) δ8.08(d,J=6.0Hz,1H),7.72(d,J=7.5Hz,2H),7.38(t,J=7.4Hz,2H),7 .35–7.28(m,4H),5.13(s,1H),2.82(q,J=7.4Hz,1H),2.04–1.86(m,2H),1.78–1.60(m,6H). 13 C NMR (101MHz, CDCl3) δ171.8,144.8,140.9,128.2,127.3,124.9,119.9,74.2,45.5,30.4,25.6.MS(ESI):m / z(%)262.2([M+H] + ).HRMS: Calculated value C 19 H 20 N:262.1590; Measured value:262.1589
[0385]
[0386] Compound 16e, reaction scale 5 mmol, 1.1 g, white solid, yield 80%. 1 H NMR(400MHz, CDCl3)δ8.03(d,J=5.2Hz,1H),7.70(d,J=7.5Hz,2H),7.40–7.34(m,2H),7 .32–7.25(m,4H),5.09(s,1H),2.39–2.26(m,1H),1.98–1.62(m,5H),1.43–1.05(m,5H). 13 C NMR (101MHz, CDCl3) δ172.2,144.9,140.9,128.2,127.3,124.9,119.9,74.4,43.7,29.9,25.9,25.4.MS(ESI):m / z(%)276.2([M+H] + ).HRMS: Calculated value C 20 H 22 N:276.1747; Measured value:276.1741
[0387]
[0388] Compound 16f, reaction scale 5 mmol, 1.3 g, white solid, yield 95%. 1H NMR(400MHz, CDCl3)δ8.14–7.99(m,1H),7.74(d,J=7.4Hz,2H),7.45–7.36(m,2H),7.32(s,4H) ,5.16(s,1H),4.10–3.89(m,2H),3.48(t,J=10.9Hz,2H),2.69–2.53(m,1H),1.91–1.67(m,4H). 13 C NMR (101MHz, CDCl3) δ169.9,144.5,140.9,128.4,127.3,124.9,120.0,74.2,67.1,40.8,29.5.MS(ESI):m / z(%)278.2([M+H] + ).HRMS: Calculated value C 19 H 20 NO:278.1540; measured value:278.1536
[0389]
[0390] Compound 16g, reaction scale 5 mmol, 1.2 g, white solid, yield 89%. 1 H NMR (400MHz, CDCl3) δ8.16(d,J=4.9Hz,1H),7.75(d,J=7.5Hz,2H),7.42(td,J=7.3,1.5Hz,2H),7.38–7.30(m,4H),5.7 7(s,2H),5.17(s,1H),2.72–2.60(m,1H),2.37–2.22(m,2H),2.21–2.13(m,2H),2.07–1.93(m,1H),1.78–1.61(m,1H). 13 C NMR (101MHz, CDCl3) δ171.3,144.7,140.9,128.2,127.2,127.0,125.3,124.8,119.9,74.4,39.4,28.2,25.8,24.0.MS(ESI):m / z(%)274.2([M+H] + ).HRMS: Calculated value C 20 H 20 N:274.1590; Measured value:274.1588
[0391]
[0392] Compound 16i, reaction scale 5 mmol, 1.78 g, white solid, yield 90%. 1H NMR (400MHz, CDCl3) δ8.16(t,J=4.4Hz,1H),7.98(d,J=8.0Hz,2H),7.70(d,J=7.6Hz,2H),7.37(t,J=7.5Hz,2H),7.31–7.22(m,4H). 7.19(d,J=7.5Hz,2H),5.13(s,1H),4.38(q,J=7.2Hz,2H),3.01(t,J=7.6Hz,2H),2.75(td,J=7.7,4.6Hz,2H),1.39(t,J=7.1Hz,3H). 13 C NMR (101MHz, CDCl3) δ166.5,166.3,146.1,144.4,140.8,130.7,129.7,128.5,128. 3,127.3,124.9,119.9,74.2,60.8,36.8,32.1,14.3.MS(ESI):m / z(%)370.2([M+H] + ).HRMS: Calculated value C 25 H 24 NO2:370.1802; measured value:370.1798
[0393]
[0394] Compound 16j, reaction scale 5 mmol, 1.35 g, white solid, yield 90%. 1 H NMR(400MHz, CDCl3)δ8.20(t,J=4.7Hz,1H),7.71(d,J=7.5Hz,2H),7.41–7.34(m,,2H),7.30–7.25(m,4H),5.92(d, J=3.1Hz,1H),5.87(d,J=3.0Hz,1H),5.15(s,1H),2.92(t,J=7.3Hz,2H),2.73(td,J=7.3,4.6Hz,2H),2.26(s,3H). 13 C NMR (101MHz, CDCl3) δ166.9,152.69,150.6,144.6,140.9,128.3,127.3,125. 0,119.9,106.2,105.9,74.4,34.4,24.9,13.5.MS(ESI):m / z(%)302.2([M+H] + ).HRMS: Calculated value C 21 H 20 NO:302.1539; Actual value:302.1537
[0395]
[0396] Compound 161, reaction scale 5 mmol, 1.14 g, yellow oil, yield 92%. 1 H NMR (400MHz, CDCl3) δ8.11(t,J=4.8Hz,1H),7.68(d,J=7.5Hz,2H),7.34(t,J=7.3Hz,2H),7.32–7.2 2(m,4H),5.92–5.77(m,1H),5.11(s,1H),5.08–4.99(m,2H),2.51–2.44(m,2H),2.40–2.30(m,2H). 13 CNMR(101MHz, CDCl3)δ167.3,144.5,140.8,137.1,128.2,127.2,124.9,119.8,115.4,74.3,34.9,30.2.MS(ESI):m / z(%)248.1([M+H] + ).HRMS: Calculated value C 18 H 18 N:248.1434; Measured value:248.1433
[0397]
[0398] Compound 16m, reaction scale 5 mmol, 0.95 g, yellow oil, yield 67%. 1 H NMR (400MHz, CDCl3) δ8.19(t,J=4.1Hz),7.72(t,J=7.6Hz,2H),7.43–7.37(m,4H),7.32(t,J=7.4Hz,2H),5.19( s,1H),2.79(d,J=6.9Hz,1H),2.72(t,J=5.9Hz,1H),2.11(s,3H),2.05(d,J=9.6Hz,1H),1.98(d,J=3.7Hz,1H). 13 C NMR (101MHz, CDCl3) δ165.8,144.3,140.6,128.1,127.1,124.8,119.2,74.1,34.8,30.2,26.7.MS(ESI):m / z(%)268.1([M+H] + ).HRMS: Calculated value C 17 H 18 NS:268.1154; Measured value:268.1157
[0399] Difluoroalkyl halides:
[0400]
[0401] The preparation method of difluoroalkyl halides is as follows:
[0402]
[0403] Compound 17d was placed in a 100 mL sealed tube, and Eosin Y (81 mg, 0.25 mmol), olefin (260 mg, 2.5 mmol), and anhydrous tetrahydrofuran (30 mL) were added. The oxygen was removed by freezing with liquid nitrogen three times. Dibromodifluoromethane (2.8 mL, 30 mmol) was added under an argon atmosphere, and the tube was sealed with a stopper. The mixture was stirred at room temperature for 10 hours under blue LED light. The product 17d was separated by concentrated column chromatography (petroleum ether), and the product was obtained as a colorless transparent liquid (250 mg) with a yield of 43%. 1 H NMR (400MHz, CDCl3) δ3.55(t,J=6.5Hz,2H),2.46–2.27(m,2H),1.81(p,J=6.7Hz,2H),1.65(p,J=7.4Hz,2H),1.60–1.50(m,2H). 13 C NMR(101MHz,CDCl3)δ122.9(t,CF,1J C-F =305.2Hz),44.5,44.1(t,CF,2J C-F =21.5Hz),32.1,25.7,23.3(t,CF,3J C-F =3.1Hz). 19 F NMR (376MHz, CDCl3) δ-43.60 (t, J = 13.7Hz). MS (EI): m / z (%) 155 ([M-Br] + ).HRMS: calculated for C6H 10 F2Cl: 155.0434; Measured value: 155.0430. IR (pure sample) νmax 3032, 2989, 2938 cm -1 .
[0404]
[0405] Preparation of compound 9j: Bromodifluoroethanol (1.6 g, 10 mmol, 1.0 equiv) and indomethacin (3.9 g, 11 mmol, 1.1 equiv) and anhydrous dichloromethane (10 mL) were added to a 50 mL egg-shaped bottle at 0°C. A dichloromethane solution (5 mL) of 1,3-dicyclohexylcarbodiimide (DCC) (3.1 g, 1.5 equiv) was slowly added dropwise. The mixture was returned to room temperature and stirred overnight. A large amount of white solid precipitated from the solution. The solution was filtered, the filtrate was concentrated, and 2.6 g of white solid was separated and purified by column chromatography (petroleum ether / ethyl acetate = 4:1). The yield was 52%, and the melting point was 117-118°C. 1 H NMR (400MHz, CDCl3) δ7.66(d,J=8.3Hz,2H),7.47(d,J=8.3Hz,2H),6.95(s,1H),6.88(d,J=9.0 Hz,1H),6.68(d,J=11.1Hz,1H),4.63(t,J=11.5Hz,2H),3.84(s,3H),3.78(s,2H),2.40(s,3H). 13 C NMR (126MHz, CDCl3) δ169.0,168.3,156.1,139.4,136.2,133.7,131.2,130.7,130.2,129.1,117.9(t,1J C-F =306.0Hz),115.0,112.0,111.3,100.9,67.2(t,2J C-F =27.5Hz),55.7,29.8,13.3. 19 F NMR (376MHz, CDCl3) δ-56.4 (t, J = 11.5Hz). MS (ESI): m / z (%) 502.0 ([M+H] + ).HRMS: Calculated value C 22 H 18 N2O4 F2Br: 500.0070; Measured value: 500.0060. IR (thin slice) νmax 1757, 1683, 1223cm -1 .
[0406]
[0407] Preparation of compound 9k: Bromodifluoroethanol (0.80 g, 5.0 mmol, 1.0 equiv) and Febuxostat (2.4 g, 7.5 mmol, 1.5 equiv) and anhydrous dichloromethane (20 mL) were added to a 50 mL egg-shaped bottle at 0 °C. An ice-water bath was used to cool the mixture to 0 °C, and a dichloromethane solution (5 mL) of 1,3-dicyclohexylcarbodiimide (DCC) (1.5 g) was slowly added dropwise. The mixture was returned to room temperature and stirred overnight. A large amount of white solid precipitated from the solution. The mixture was filtered, the filtrate was concentrated, and 1.83 g of white solid was obtained by column chromatography (petroleum ether / ethyl acetate = 5:1). The yield was 80%, and the melting point was 129–131 °C. 1 H NMR (400MHz, CDCl3) δ8.20(d,J=2.0Hz,1H),8.09(dd,J=8.8,2.0Hz,1H),7.02(d,J=8.9Hz,1H),4.80(t, J=11.3Hz,2H),3.90(d,J=6.4Hz,2H),2.78(s,3H),2.20(hept,J=6.5Hz,1H),1.10(s,3H),1.08(s,3H). 13 C NMR (101MHz, CDCl3) δ168.6,163.1,162.7,160.0,132.7,132.2,125.7,119.8,117.9(t,1J C-F =307.1Hz),115.2,112.7,103.1,67.3(t,2J C-F =28.0Hz),28.1,19.0,17.7. 19 F NMR (376MHz, CDCl3) δ-56.4 (t, J = 11.3Hz). MS (ESI): m / z (%) 459.0 ([M+H] + ).HRMS: Calculated value C 18 H 18 N2O3F2SBr: 459.0184; Found: 459.0179. IR (thin slice) νmax 2955, 2222, 1722cm -1 Example 6 Nickel-catalyzed coupling reaction of 2-azirallyl anion with non-activated difluoroalkyl halide
[0408]
[0409] Add L22 (4.9 mg, 12 mol%) and 16 (0.3 mmol, 1.5 equiv) to a 25 mL sealed tube, take the sealed tube into a glove box and add NiCl2·DME (4.4 mg, 10 mol%). Take the sealed tube out of the glove box and connect it to a double row, replace the gas three times, add tetrahydrofuran (1 mL) under argon atmosphere, and pre-stir for 20 minutes. Then, add LiHMDS (0.3 mL, 1.0 M LiHMDS in THF solution, 1.5 equiv) dropwise to the sealed tube at 0°C. After the addition is complete, add 17 (0.2 mmol, 1.0 equiv) and rinse with tetrahydrofuran (1 mL). Return to room temperature and react for 2 hours. Before post-reaction treatment, NMR 19 F was used to determine the yield by nuclear magnetic resonance (fluorobenzene was used as the internal standard). After the reaction was completed, NaBH4 (24 mg, 3.0 equiv) was added to the reaction system, and diluted with dichloromethane (3 mL), and glacial acetic acid (0.22 mL, 20 equiv) was slowly added dropwise thereto. At this time, the system was turbid and a large number of bubbles emerged. After stirring at room temperature for 1 hour, 10% aqueous sodium hydroxide solution (1.6 mL) was added to the system. Stirring was continued at room temperature for 20 minutes, and the system gradually became clear. The aqueous phase was extracted with dichloromethane (25 mL×3), and the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated by column chromatography to obtain the target product.
[0410]
[0411] Compound 18a was purified by column chromatography (petroleum ether / ethyl acetate = 15:1) to give 75 mg of a yellow oil with a yield of 80%. 1 HNMR (400MHz, CDCl3) δ7.67 (dd, J=7.5, 5.2Hz, 2H), 7.52 (d, J=7.5Hz, 1H), 7.49 (d, J= 7.5Hz,1H),7.36(t,J=7.5Hz,2H),7.31–7.19(m,9H),7.15(t,J=7.3Hz,1H),7.03(d,J =7.4Hz,2H),4.99(s,1H),3.84(s,2H),3.60–3.45(m,1H),3.33–3.19(m,1H),3.15–2. 99(m,1H),2.74–2.55(m,2H),2.10–1.95(m,1H),1.80(s(br),2H),1.73–1.61(m,1H). 13C NMR (101MHz, CDCl3) δ146.4,146.1,141.6,140.5,140.1,139.7,128.43,128.3 5,128.34,128.18,128.15,128.12,127.4,127.3,127.1,125.9,125.3(t,CF,1J C-F =247.1Hz),125.1,125.0,120.0,119.8,62.2,57.8(t,CF,2J C-F =24.8Hz),53.8,50.4(t,CF,2J C-F =26.8Hz),32.6,32.4. 19 F NMR (376MHz, CDCl3) δ-107.1 (dtd, J=252.2, 16.3, 8.5Hz), -110.6 (dq, J=252.4, 14.1Hz). MS (EI): m / z (%) 469.2 ([M+H] + ).HRMS: Calculated value C 31 H 31 F2N2:469.2450; Measured value:469.2447.IR (thin sheet)νmax3026,2927,1716cm -1 .
[0412]
[0413] Compound 18b was purified by column chromatography (petroleum ether / ethyl acetate = 20:1) to give 89 mg of a yellow oil with a yield of 90%. 1 HNMR(400MHz, CDCl3)δ7.71(dd,J=7.6,3.4Hz,2H),7.63(d,J=7.4Hz,1H),7.54(d,J=7.5Hz,1H),7.4 2–7.35(m,2H),7.34–7.29(m,1H),7.26(t,J=6.9Hz,3H),7.18(t,J=7.0Hz,1H),7.09(d,J=7.4Hz,2H ),5.05(s,1H),4.21–4.06(m,1H),4.02–3.86(m,J=11.9Hz,1H),3.70–3.56(m,1H),2.71(t,J=8.2Hz ,2H),2.20–2.01(m,1H),1.80–1.69(m,1H),1.65(s(br),1H),0.92(s,9H),0.13(s,3H),0.11(s,3H). 13C NMR (126MHz, CDCl3) δ146.5,146.3,141.7,140.4,140.1,128.4,128.3,128.12,128.09,127.38,127.27,125.87(t,1J C-F =247.7Hz),125.84,125.09,125.04,119.94,119.77,62.8(dd,2J C-F =33.8,31.9Hz),62.4,56.6(t,2J C-F =24.1Hz),32.6,32.1,25.7,18.2,-5.4. 19 F NMR (376MHz, CDCl3) δ-112.5 (ddt, J=253.0, 19.3, 10.3Hz), -116.3 (dtd, J=252.7, 14.6, 9.9Hz). MS (ESI): m / z (%) 494.4 ([M+H] + ).HRMS: Calculated value C 30 H 38 NOF2Si: 494.2685; Measured value: 494.2688. IR (thin slice) νmax 2953, 2953, 2929, 2857, 1255cm -1 .
[0414]
[0415] Compound 18c was purified by column chromatography (petroleum ether / ethyl acetate = 20:1) to give 87 mg of a yellow oil with a yield of 90%. 1 HNMR (400MHz, CDCl3) δ7.67(dd,J=7.0,4.6Hz,2H),7.55(dd,J=6.9,4.0Hz,2H),7.36(t,J=7.4Hz,2H),7.31–7.23(m,4H),7.23–7.11(m,6H),7.01 (d,J=7.1Hz,2H),4.99(s,1H),3.43–3.17(m,1H),2.72–2.50(m,4H),2.2 2–2.06(m,1H),2.00–1.86(m,2H),1.73–1.63(m,2H),1.62–1.49(m,4H). 13 C NMR (126MHz, CDCl3) δ146.5 146.2,142.3,141.4,140.4,140.1,128.4,128.3,128.2,128.2,127.4,127.2,126.7(t,CF,1JC-F =244.4Hz),125.9,125.7,125.2,125.1,112.0,119.8,62.5,59.3(t,2J C-F =25.2Hz),35.8,32.8,32.7,32.4(t,CF,2J C-F =24.5Hz),31.4,21.2(t,CF,3J C-F =4.1Hz). 19 F NMR (376MHz, CDCl3) δ-104.0 (ddt, J=246.4, 27.2, 10.0Hz, 1F), -105.7 (ddt, J=246.3, 27.1, 10.3Hz, 1F). MS (ESI): m / z (%) 482.3 ([M+H] + ).HRMS: Calculated value C 33 H 34 NF2: 482.2654; Measured value: 482.2648. IR (thin sheet) νmax 3025, 2936, 1603cm -1 .
[0416]
[0417] Compound 18d was purified by column chromatography (petroleum ether / ethyl acetate = 20:1) to give 86 mg of a yellow oil. The yield was 95%. 1 HNMR(400MHz, CDCl3) δ7.67(dd,J=7.2,4.1Hz,2H),7.55(d,J=7.4Hz,2H),7.36(t,J=7.4H z,2H),7.27(dt,J=13.3,8.0Hz,2H),7.22(t,J=7.5Hz,2H),7.14(t,J=7.2Hz,1H),7.02(d ,J=7.2Hz,2H),4.99(s,1H),3.53(t,J=6.6Hz,2H),3.37–3.24(m,1H),2.83–2.41(m,J=6. 1Hz,2H),2.23–2.02(m,1H),2.00–1.85(m,2H),1.79(p,J=6.7Hz,2H),1.66–1.43(m,6H). 13 C NMR (101MHz, CDCl3) δ146.4,146.2,141.4,140.5,140.1,128.4,128.3,128.2,127.4,127.2,126.6(t,1J C-F=245.9Hz),125.9,125.2,125.1,120.0,119.8,62.4,59.3(dd,2J C-F =26.6,25.0Hz),44.8,32.8,32.7,32.4,32.4(t,2J C-F =24.8Hz),26.8,20.7(t,J C-F =4.4Hz). 19 F NMR(376MHz, CDCl3)δ-107.7(ddt,J=246.7,27.5,9.6Hz,1F),-109.64(ddt,J=246.5,27.4,10.1Hz,1F).).MS(ESI):m / z(%)454.2([M+H] + ).HRMS: Calculated value C 28 H 31 NF2Cl: 454.2108; Measured value: 454.2104. IR (thin slice) νmax 3062, 2939, 2866cm -1 .
[0418]
[0419] Compound 18e was purified by column chromatography (petroleum ether / ethyl acetate = 20:1-10:1) to give 72 mg of a yellow oil with a yield of 84%. 1 H NMR(500MHz, CDCl3) δ7.71(dd,J=7.5,5.3Hz,2H),7.56(t,J=7.0Hz,2H),7.40(t,J =7.5Hz,2H),7.35–7.28(m,2H),7.25(t,J=7.5Hz,2H),7.18(t,J=7.3Hz,1H),7.04( d,J=7.3Hz,2H),5.01(s,1H),3.38–3.26(m,1H),2.70–2.54(m,2H),2.37(t,J=6.8H z,2H),2.25–2.07(m,2H),2.00–1.87(m,2H),1.80–1.65(m,4H),1.69–1.58(m,1H). 13 C NMR (126MHz, CDCl3) δ146.2,146.0,141.2,140.5,140.1,128.4,128.3,128.2,127.4,127.3,126.3,126.0(t,1J C-F=246.0Hz),125.14,125.05,120.0,119.9,119.4,62.4,59.1(dd,CF,2J C-F =26.7,24.7Hz),32.8,32.7,31.5(t,CF,2J C-F =24.7Hz),25.3,20.8(t,CF,3J C-F =4.4Hz),17.1. 19 F NMR (376MHz, CDCl3) δ-108.7 (ddt, J=247.3, 28.2, 9.0Hz, 1F), -111.1 (ddt, J=247.3, 27.8, 9.7Hz, 1F). MS (ESI): m / z (%) 431.2 ([M+H] + ).HRMS: Calculated value C 28 H 29 N2F2: 431.2293; Measured value: 431.2295. IR (thin sheet) νmax 3025, 2937, 2247cm -1 .
[0420]
[0421] Compound 18f was purified by column chromatography (petroleum ether / dichloromethane = 10:1-5:1) to give 69 mg of a yellow oil with a yield of 75%. 1 H NMR (400MHz, CDCl3) δ7.70(dd,J=7.5,5.0Hz,2H),7.57(t,J=6.5Hz,2H),7.39(t,J=7.5Hz, 2H),7.30(dd,J=13.9,7.2Hz,2H),7.23(d,J=7.5Hz,2H),7.16(t,J=7.3Hz,1H),7.06–7.01( m,2H),5.02(s,1H),4.16(q,J=7.1Hz,2H),3.43–3.30(m,1H),2.71–2.53(m,2H),2.41(t,J= 7.2Hz,2H),2.32–2.10(m,1H),2.06–1.84(m,4H),1.70–1.53(m,2H),1.28(t,J=7.1Hz,3H). 13 C NMR (126MHz, CDCl3) δ173.1,146.4,146.2,141.3,140.4,140.1,128.4,128.3,128.2,127.4,127.3,126.5(t,CF,1J C-F=245.8Hz),126.0,125.2,125.1,120.0,119.8,62.5,60.4,59.4(dd,CF,2J C-F =26.7,24.5Hz),33.9,32.8,32.7,31.6(t,CF,2J C-F =24.5Hz),17.1(t,CF,J C-F =4.5Hz),14.2. 19 F NMR (376MHz, CDCl3) δ-104.0 (ddt, J=246.8, 26.7, 9.0Hz), -106.0 (ddt, J=246.9, 29.1, 9.4Hz). MS (ESI): m / z (%) 464.2 ([M+H] + ).HRMS: Calculated value C 29 H 32 NO2F2: 464.2396; Measured value: 464.2389. IR (thin slice) νmax 2977, 1732, 1179cm -1
[0422]
[0423] Compound 18g was separated by thick preparative plate (petroleum ether / ethyl acetate=10:1) to give 68mg of a yellow oil with a yield of 62%. 1 H NMR(400MHz, CDCl3) δ7.98(d,J=8.5Hz,2H),7.69(t,J=6.5Hz,2H),7.58–7.51( m,2H),7.44–7.33(m,4H),7.30–7.19(m,4H),7.17(t,J=7.2Hz,1H),7.03(d,J=7 .2Hz,2H),5.01(s,1H),4.40(t,J=5.4Hz,2H),3.44–3.31(m,1H),2.71–2.53(m, 2H),2.44–2.21(m,1H),2.18–1.89(m,4H),1.72–1.63(m,1H),1.61(s(br),1H). 13 C NMR (126MHz, CDCl3) δ165.7,146.3,146.1,141.3,140.5,140.1,139.4,131.0,128.8,128.7,128.5,128.33,128.29,127.4,127.3,126.5(t,CF,1J C-F=245.6Hz),126.1,125.2,125.1,120.1,119.9,64.7,62.5,59.4(dd,CF,2J C-F =27.1,24.6Hz),32.9,32.8,29.2(t,CF,2J C-F =24.8Hz),21.2(t,J=4.4Hz). 19 F NMR (376MHz, CDCl3) δ-103.8 (ddt, J=246.7, 27.0, 8.5Hz), -106.6 (ddt, J=246.2, 28.6, 11.9Hz). MS (ESI): m / z (%) 546.2 ([M+H] + ).HRMS: Calculated value C 33 H 31 NO2F2Cl: 546.2006; Measured value: 546.1985. IR (thin slice) νmax 2958, 1716, 1401cm -1 .
[0424]
[0425] Compound 18h was purified by column chromatography (petroleum ether / ethyl acetate = 50:1-20:1) to give 77 mg of a yellow oil with a yield of 90%. 1 H NMR (500MHz, CDCl3) δ7.71(d,J=7.5Hz,2H),7.60(d,J=7.5Hz,1H),7.57(d,J=7.5Hz,1H ),7.39(td,J=7.3,1.9Hz,2H),7.34–7.27(m,2H),7.24(t,J=7.4Hz,2H),7.16(t,J=7.3H z,1H),7.03(d,J=7.1Hz,2H),5.03(s,1H),3.29–3.17(m,1H),2.67–2.53(m,2H),2.18–2 .02(m,1H),1.97–1.88(m,1H),1.87–1.74(m,4H),1.73–1.62(m,3H),1.34–1.07(m,5H). 13 C NMR (126MHz, CDCl3) δ146.4,145.9,141.9,140.5,140.3,128.4,128.3,128.1,127.4,127.2,126.7(t,CF,1J C-F =254.5Hz),125.8,125.2,125.1,119.9,62.4,56.4(dd,CF,2JC-F =25.8,24.2Hz),40.9(t,CF,2J C-F =23.0Hz),32.8,32.6,26.0,25.8,25.7,25.6(t,CF,3J C-F =4.6Hz),25.1(t,CF,3J C-F =4.6Hz). 19 F NMR (376MHz, CDCl3) δ-114.7 (dt, J=248.6, 14.0Hz, 1F), -115.6 (dt, J=247.6, 12.7Hz, 1F). MS (ESI): m / z (%) 432.2 ([M+H] + ).HRMS: Calculated value C 29 H 32 NF2: 432.2497; Measured value: 432.2496. IR (thin sheet) νmax 3025, 2933, 2854 cm -1 .
[0426]
[0427] Compound 18i was purified by column chromatography (petroleum ether / ethyl acetate = 15:1-10:1) to give 90 mg of a yellow oil with a yield of 82%. 1 H NMR (400MHz, CDCl3) δ7.68(dd,J=7.0,4.9Hz,2H),7.54(t,J=7.0Hz,2H),7.37(t,J=7.3Hz,2H),7.29( dd,J=13.8,7.2Hz,2H),7.25–7.21(m,2H),7.16(t,J=7.1Hz,1H),7.03(d,J=7.2Hz,2H),5.00(s,1H), 4.19–3.92(m,2H),3.43–3.26(m,1H),2.79–2.67(m,2H),2.66–2.55(m,2H),2.15–2.00(m,1H),1.99– 1.90(m,1H),1.90–1.84(m,1H),1.83–1.70(m,2H),1.65–1.54(m,2H),1.46(s,9H),1.25–1.13(m,2H). 13 C NMR (101MHz, CDCl3) δ154.8,146.4,146.2,141.3,140.4,140.1,128.4,128.3,128.22,128.21,127.4,127.3,127.0(t,CF,1J C-F=246.8Hz),126.0,125.2,125.1,120.0,119.8,79.3,62.5,59.8(t,CF,2J C-F =25.7Hz),43.8,38.4(t,CF,2J C-F =23.4Hz),32.84(t,CF,J C-F =12.1Hz),32.76,30.2,28.5. 19 F NMR(376MHz, CDCl3)δ-99.4–-102.1(m),-102.2–-104.0(m).MS(ESI):m / z(%)547.3([M+H] + ).HRMS: Calculated value C 34 H 40 O2N2F2: 547.3131; Measured value: 547.3122. IR (thin sheet) νmax 2972, 2926, 1692cm -1
[0428]
[0429] Compound 18j was purified by column chromatography (petroleum ether / ethyl acetate = 20:1-10:1) to give 86 mg of a yellow solid with a yield of 60% and a melting point of 89-90°C. 1 H NMR (400MHz, CDCl3) δ7.68(d,J=2.9Hz,1H),7.66(d,J=3.0Hz,1H),7.55(d,J=8.0Hz,2H),7.50(d,J=7.5Hz,1H),7.42–7.37(m, 4H),7.35(d,J=3.0Hz,1H),7.28(d,J=7.4Hz,1H),7.25–7.20(m,3H),7.16(t,J=7.2Hz,1H),6.99(d,J=7.3Hz,2H),6.95(d,J=2. 5Hz,1H),6.81(d,J=9.0Hz,1H),6.63(dd,J=9.0,2.5Hz,1H),4.75(s,1H),4.75–4.58(m,1H),4.57–4.47(m,1H),3.78(s,3H),3. 73(d,J=3.1Hz,2H),3.32–3.20(m,1H),2.62–2.44(m,2H),2.33(s,3H),2.01–1.90(m,1H),1.70–1.60(m,1H),1.57(s(br),1H). 13C NMR (126MHz, CDCl3) δ169.9,168.1,156.0,145.8,145.5,141.1,140.5,140.0,139.2,136.0,133.7, 131.1,130.6,130.3,129.0,128.4,128.3,128.2,127.5,127.3,126.0,125.2,125.0,122.7(t,CF,1J C-F =247.8Hz),120.0,119.9,115.0,111.89,111.85,100.9,62.6(dd,CF,2J C-F =32.0,27.6Hz),62.5,57.1(t,CF,2J C-F =24.6Hz),55.5,32.6,32.3,30.1,13.3. 19 F NMR (376MHz, CDCl3) δ-109.5 (dtd, J=256.7, 15.9, 7.0Hz), -116.3 (dtd, J=256.7, 15.3, 8.1Hz). MS (ESI): m / z (%) 719.3 ([M+H] + ).HRMS: Calculated value C 43 H 38 N2O4F2Cl: 719.2483; Measured value: 719.2482. IR (thin slice) νmax 2930, 1746, 1684cm -1 .
[0430]
[0431] Compound 18k was purified by column chromatography (petroleum ether / ethyl acetate = 10:1-5:1) to give a yellow solid (75 mg, yield 55%), melting point 75-76°C. 1H NMR(400MHz, CDCl3)δ8.13(d,J=1.9Hz,1H),8.06(dd,J=8.8,2.1Hz,1H),7.73–7.65(m,2H),7.58(d,J=7.5Hz,1H),7 .53(d,J=7.6Hz,1H),7.40(t,J=7.6Hz,1H),7.30(q,J=6.8Hz,2H),7.24–7.19(m,3H),7.19–7.13(m,1H),7.04–6.97( m,3H),5.02(s,1H),4.85–4.61(m,2H),3.91(d,J=6.5Hz,2H),3.42–3.27(m,1H),2.72(s,3H),2.68–2.60(m,1H),2. 61–2.48(m,1H),2.22(hept,J=6.6Hz,1H),2.13–2.09(m,1H),1.79–1.69(m,1H),1.66(s,1H),1.11(d,J=6.7Hz,6H). 13 C NMR (126MHz, CDCl3) δ167.8,162.6,162.2,160.8,145.7,145.2,141.0,140.6,140.2,132.6 ,132.1,128.4,128.34,128.31,127.43,127.36,126.0,125.7,125.2,125.1,122.6(t,CF,1J C-F =248.4Hz)120.6,120.00,119.97,115.3,112.6,103.0,75.7,62.5(t,CF,2J C-F =29.3Hz),62.2,56.3(t,CF,2J C-F =24.5Hz),32.6,32.4,28.1,19.0,17.5. 19 F NMR (376MHz, CDCl3) δ-109.6 (dtd, J=259.5, 14.9, 6.6Hz), -116.1 (dtd, J=259.3, 12.6, 12.6Hz). MS (ESI): m / z (%) 678.3 ([M+H] + ).HRMS: Calculated value C 40 H 38 N3O3F2S: 678.2697; Measured value: 678.2588. IR (thin slice) νmax 2961, 2929, 2229, 1723cm -1 .
[0432]
[0433] Compound 19a was purified by column chromatography (petroleum ether / ethyl acetate = 10:1-5:1) to give 64 mg of a yellow oil with a yield of 80%. 1 H NMR (400MHz, CDCl3) δ7.68(t,J=8.1Hz,2H),7.55(d,J=7.4Hz,2H),7.39–7.32(m,2H),7.31–7.27(m,4 H),7.26–7.20(m,3H),5.06(s,1H),2.72(t,J=7.4Hz,2H),2.72–2.63(m,1H),2.44–2.20(m,1H),2.15– 2.00(m,1H),1.99–1.89(m,2H),1.73(s(br),1H),0.71(qt,J=9.5,5.3Hz,1H),0.51(tt,J=8.8,5.7Hz ,1H),0.41(dq,J=10.4,5.5Hz,1H),0.26(ddd,J=14.1,8.8,5.6Hz,1H),-0.07(dq,J=10.5,5.3Hz,1H). 13 C NMR (126MHz, CDCl3) δ147.3,146.4,141.8,140.4,139.9,128.44,128.36,128.0,127.9,127.3,127.2,126.5(t,CF,1J C-F =245.8Hz),125.9,125.1,124.8,119.9,119.7,64.8(dd,CF,2J C-F =26.2,23.7Hz),61.9,35.6,31.9(t,CF,2J C-F =24.4Hz), 23.1 (t, CF, J = 4.1 Hz), 12.4 (dd, CF, J = 5.9, 1.9 Hz), 3.9, 3.5. 19 F NMR(376MHz, CDCl3)δ-103.0(ddt,J=245.8,27.8,9.7Hz),-104.0(ddt,J=246.4,25.3,10.0Hz).).MS(ESI):m / z(%)404.2([M+H] + ).HRMS: Calculated value C 27 H 28 NF2: 404.2184; Measured value: 404.2180. IR (thin sheet) νmax 3024, 2870, 1717cm -1
[0434]
[0435] Compound 19b was purified by column chromatography (petroleum ether / ethyl acetate = 10:1-5:1) to give 85 mg of a yellow oil with a yield of 82%, 1:1 rotational isomers. 1 H NMR(400MHz, CDCl3) δ7.93(d,J=7.8Hz,1H),7.77(d,J=7.5Hz,1H),7.73–7.6 4(m,3H),7.63(d,J=7.5Hz,1H),7.60(d,J=7.5Hz,1H),7.50–7.42(m,3H),7.3 8(td,J=7.4,3.1Hz,2H),7.34–7.27(m,6H),7.20(dt,J=13.2,7.5Hz,5H),7. 13(d,J=7.0Hz,1H),7.05(d,J=7.2Hz,2H),5.10(dt,J=13.9,7.2Hz,1H),4.98 (s,1H),4.06(t,J=8.7Hz,1H),4.00–3.89(m,3H).3.88–3.81(m,2H),3.76(t ,J=8.7Hz,1H),3.69(q,J=8.2,7.2Hz,2H),3.34(h,J=7.0Hz,1H).2.81–2.74( m,1H),2.71(q,J=7.1Hz,2H),2.58(h,J=6.4Hz,2H),2.22–1.99(m,2H),2.00– 1.90(m,4H),1.89–1.73(m,4H),1.72–1.60(m,1H),1.40(s,9H),1.37(s,9H). 13 C NMR (126MHz, CDCl3) δ165.3,156.2,156.1,146.5,145.9,144.6,141.34,141.32,140.9,140.2,140.0,138.2,132.0,13 1.8,131.6,128.43,128.40,128.36,128.31,128.25,128.23,127.5,127.4,127.1,126.0,125.8,125.0,124.9(t,CF,1J C-F =245.1Hz),124.7,123.2,120.7,120.2,119.8,119.3,79.5,79.3,65.6(t,CF,2J C-F =27.0Hz),62.38,62.37,61.8(t,CF,2JC-F =26.0Hz),51.4,35.31,35.25,32.9(t,CF,2J C-F =24.1Hz),32.0(t,CF,2J C-F =25.6Hz),29.9,29.7,28.31,28.30,22.9(t,CF,J C-F =4.3Hz),22.8(t,CF,J C-F =3.6Hz). 19 F NMR(376MHz, CDCl3)δ-93.4–-110.2(m).MS(ESI):m / z(%)517.3([MH] + ).HRMS: Calculated value C 32 H 35 NF2O2: 517.2661; Measured value: 517.2647. IR (thin slice) νmax 2973, 2888, 1699cm -1 .
[0436]
[0437] Compound 19c was purified by column chromatography (petroleum ether / ethyl acetate = 50:1) to give 69 mg of a yellow oil with a yield of 80%. 1 HNMR (400MHz, CDCl3) δ7.65 (dd, J=10.2, 7.6Hz, 3H), 7.50 (d, J=7.4Hz, 1H), 7.38–7.30(m,3H),7.30–7.26(m,2H),7.26–7.20(m,4H),5.01(s,1H),3.56 (td,J=9.7,6.5Hz,1H),2.75(hept,J=6.9,6.5Hz,2H),2.40–2.20(m,1H),2 .08–1.84(m,4H),1.83–1.67(m,2H),1.64–1.41(m,5H),1.37–1.22(m,2H). 13 C NMR (126MHz, CDCl3) δ147.4,146.9,141.7,140.2,139.8,128.5,128.4,128.0,127.9,127.42,127.37(t,CF,1J C-F =245.6Hz),127.1,125.9,125.3,124.9,120.0,119.5,63.9(t,CF,2J C-F =24.3Hz),63.1,41.4(t,CF,J C-F=2.8Hz),35.5,31.8(t,CF,2J C-F =24.4Hz),30.6,28.7,25.0,24.6,23.0(t,CF,J C-F =4.1Hz). 19 FNMR (376MHz, CDCl3) δ-101.1 (td, J=18.4, 9.7Hz).MS (ESI): m / z (%) 432.2 ([M+H] + ).HRMS: Calculated value C 29 H 32 NF2: 432.2497; Measured value: 432.2492. IR (thin sheet) νmax 3025, 2954, 2869, 1603cm -1 .
[0438]
[0439] Compound 19d was purified by column chromatography (petroleum ether / ethyl acetate = 50:1) to give 56 mg of a yellow oil. The yield was 63%. 1 HNMR(400MHz, CDCl3) δ7.68(t,J=7.0Hz,2H),7.62(d,J=7.4Hz,1H),7.59(d,J=7.5 Hz,1H),7.37(t,J=7.4Hz,2H),7.34–7.27(m,4H),7.25–7.19(m,3H),5.02(s,1H),3 .29(td,J=12.5,3.4Hz,1H),2.72(t,J=7.1Hz,2H),2.24–2.06(m,1H),2.01–1.88( m,3H),1.81–1.52(m,8H),1.48–1.36(m,1H),1.32–1.18(m,1H),1.15–1.06(m,2H). 13 C NMR (126MHz, CDCl3) δ147.2,146.9,141.7,140.2,140.0,128.43,128.38,128.02,127.92,127.4,127.16(t,CF,1J C-F =246.0Hz),127.12,125.9,125.1,124.9,119.9,119.7,65.2(t,CF,2J C-F =23.3Hz),63.3,39.5,35.5,33.5(t,CF,2J C-F =24.7Hz),31.3,28.2,26.8,26.5,26.1,23.4(t,CF,JC-F =4.4Hz). 19 F NMR (376MHz, CDCl3) δ-101.2 (td, J=17.5, 12.1Hz).MS (ESI): m / z (%) 446.3 ([M+H] + ).HRMS: Calculated value C 30 H 34 NF2:446.2654; Measured value:446.2649.IR (thin sheet)νmax3025,2926,2852,1450cm -1 .
[0440]
[0441] Compound 19e was purified by column chromatography (petroleum ether / ethyl acetate = 40:1-20:1) to give 55 mg of a colorless oil. The yield was 62%. 1 H NMR (400MHz, CDCl3) δ7.73–7.65(m,2H),7.60(d,J=7.4Hz,1H),7.55(d,J=7.4Hz,1H),7.38(t,J=7.4H z,2H),7.34–7.26(m,4H),7.22(t,J=7.2Hz,3H),5.00(s,1H),3.96(dd,J=11.0,3.8Hz,1H),3.90(dd,J =11.4,2.7Hz,1H),3.34–3.26(m,2H),3.22(td,J=11.8,2.6Hz,1H),2.71(t,J=7.1Hz,2H),2.22–2.04 (m,1H),2.01–1.86(m,3H),1.82–1.70(m,2H),1.65(s(br),1H),1.59–1.51(m,2H),1.49–1.40(m,1H). 13 C NMR (126MHz, CDCl3) δ146.7,146.5,141.5,140.2,140.0,128.42,128.40,128.2,128.1,127.4,127.2,126.8(t,CF,1J C-F =246.2Hz),126.0,125.0,124.9,68.1,67.99,67.95,64.1(t,CF,2J C-F =23.8Hz),63.1,36.9,35.4,33.3(t,CF,2J C-F =24.6Hz),30.7,28.6,25.6,23.2(t,CF,J C-F =4.1Hz).19 F NMR (376MHz, CDCl3) δ-101.1 (ddt, J=248.2, 23.3, 12.5Hz), -101.9 (ddt, J=248.2, 23.8, 12.1Hz) MS (ESI): m / z (%) 448.2 ([M+H] + ).HRMS: Calculated value C 29 H 32 NF2O: 448.2447; Measured value: 448.2446. IR (thin slice) νmax 2949, 2842, 1495cm -1 .
[0442]
[0443] Compound 19f was purified by column chromatography (petroleum ether / ethyl acetate = 50:1) to give 66 mg of a colorless oil with a yield of 70%, a diastereomeric mixture, dr = 1.2:1. 1 H NMR (500MHz, CDCl3) δ7.72 (dd, J=11.3, 6.5Hz, 1H), 7.70–7.66 (m, 2H), 7.63 (dd, J=13. 2,7.5Hz,1H),7.37(t,J=7.4Hz,2H),7.33–7.27(m,2H),5.70–5.58(m,1H),5.63(s,1H) ,5.07(s,1H),4.15–4.01(m,1H),3.96–3.80(m,1H),3.79–3.62(m,1H),2.16–2.04(m,3 H),2.03–1.98(m,1H),1.84–1.76(m,1H),1.76–1.55(m,3H),0.93(s,9H),0.13(s,6H). 13 C NMR (126MHz, CDCl3) δ147.2,147.0,146.8,140.24,140.21,140.12,140.04,128.14,128.09,128.04 ,127.99,127.45,127.41,127.21,127.18,126.77,126.62,126.42,125.02,124.98,124.82(t,CF,1J C-F =248.2Hz),124.49(t,CF,1J C-F =248.2Hz),119.98,119.93,119.76,119.74,63.43(t,CF,2J C-F =33.7Hz),63.38(t,CF,2JC-F =33.7Hz),63.23,63.01,61.27(t,CF,2J C-F =21.9Hz),61.19(t,CF,2J C-F =22.2Hz),35.09,35.03,29.9,27.2,26.4,25.84,25.82,25.78,25.77,24.08,18.25,18.24,-5.37,-5.40. 19 F NMR(376MHz, CDCl3)δ-109.0–-113.0(m).MS(ESI):m / z(%)470.3([M+H] + ).HRMS: Calculated value C 28 H 38 NOF2Si: 470.2685; Measured value: 470.2674. IR (thin slice) νmax 2952, 2928, 1716cm -1
[0444]
[0445] Compound 19g was purified by column chromatography (petroleum ether / ethyl acetate = 40:1) to give 78mg of a colorless oil with a yield of 90%. 1 HNMR (400MHz, CDCl3) δ7.71–7.54(m,4H),7.34(t,J=6.9Hz,2H),7.26(dt,J=10.0 ,5.3Hz,4H),7.22–7.14(m,3H),4.99(s,1H),3.53–3.40(m,1H),2.66(t,J=7.2Hz, 2H),2.34–2.12(m,1H),1.98–1.77(m,1H),1.76–1.61(m,4H),1.60–1.52(m,1H), 1.42(s(br),1H),1.30–1.13(m,2H),0.87(d,J=6.3Hz,3H),0.77(d,J=6.5Hz,3H). 13 C NMR (126MHz, CDCl3) δ146.8,146.8,142.3,140.4,140.0,128.4,128.3,128.10,128.17,127.4,127.2,127.1(t,CF,1J C-F =244.9Hz),125.7,125.3,124.9,120.0,119.7,62.6(d,CF,J C-F =2.7Hz),58.4(dd,CF,2JC-F =28.3,23.5Hz),40.5,35.8,31.7(t,2J C-F =24.8Hz),31.5,24.6,23.4,22.1,21.0(t,J=4.0Hz). 19 F NMR (376MHz, CDCl3) δ-102.8 (ddt, J=245.6, 28.6, 9.4Hz.1F), -105.30 (ddt, J=245.9, 29.2, 8.9Hz, 1F). MS (ESI): m / z (%) 434.3 ([M+H] + ).HRMS: Calculated value C 29 H 34 NF2: 434.2654; Measured value: 434.2655. IR (thin sheet) νmax 3025, 2957, 2868cm -1 .
[0446]
[0447] Compound 19h was purified by column chromatography (petroleum ether / ethyl acetate = 40:1) to give 81 mg of a yellow oil. The yield was 75%. 1 HNMR(400MHz, CDCl3)δ7.88(dd,J=8.2,1.4Hz,2H),7.68(dd,J=7.7,4.0Hz,2H),7.52–7.44(m,2H),7 .37(t,J=7.5Hz,2H),7.33–7.24(m,4H),7.21(t,J=8.3Hz,3H),7.01(d,J=7.9Hz,2H).4.98(s,1H),4. 36(q,J=7.1Hz,2H),3.26–3.14(m,1H),2.69(t,J=7.4Hz,2H),2.65–2.49(m,2H),2.20–2.06(m,1H), 2.03–1.91(m,1H),1.88(q,J=7.2Hz,3H),1.60(s(br),1H),1.56–1.48(m,1H),1.38(t,J=7.1Hz,3H). 13 C NMR (126MHz, CDCl3) δ166.5,146.8,146.3,145.8,141.6,140.5,140.1,129.6, 128.41,128.39,128.3,128.22,128.21,128.19,127.4,127.3,126.5(t,CF,1J C-F=245.6Hz),125.9,125.1,120.0,119.9,62.3,60.8,58.8(t,CF,2J C-F =25.8Hz),35.4,32.6,32.4,32.1(t,CF,2J C-F =24.5Hz),23.0(t,CF,J C-F =3.9Hz),14.3. 19 F NMR (376MHz, CDCl3) δ-103.8 (ddt, J=246.6, 26.0, 9.4Hz, 1F), -106.2 (ddt, J=246.6, 27.0, 10.0Hz, 1F). MS (ESI): m / z (%) 540.3 ([M+H] + ).HRMS: Calculated value C 35 H 40 NF2O2: 540.2709; Measured value: 540.2710. IR (thin slice) νmax 2936, 1716, 852cm -1
[0448]
[0449] Compound 19i was purified by column chromatography (petroleum ether / ethyl acetate = 50:1) to give 85 mg of a yellow oil with a yield of 90%. 1 HNMR (400MHz, CDCl3) δ7.68(t,J=7.1Hz,2H),7.55(d,J=7.5Hz,1H),7.49(d,J=7.4Hz,1H),7.37(t ,J=7.6Hz,2H),7.33–7.24(m,4H),7.22(t,J=6.3Hz,3H),5.81(d,J=3.0Hz,1H),5.76(d,J=3.0Hz, 1H),4.97(s,1H),3.48–3.35(m,1H),2.70(td,J=7.0,2.1Hz,2H),2.64(q,J=9.1Hz,2H),2.21(s,3 H),2.19–2.09(m,1H),2.03–1.96(m,1H),1.95–1.86(m,3H),1.69–1.57(m,1H),1.53(s(br),1H). 13 C NMR (126MHz, CDCl3) δ153.1,150.4,146.5,146.4,141.7,140.3,140.0,128.42,128.38,128.12,128.10,127.4,127.3,126.7(t,CF,1JC-F =245.5Hz),125.9,125.2,124.9,119.9,119.7,105.83,105.82,62.47,59.4(t,CF,2J C-F =25.7Hz)),35.5,31.9(t,CF,2J C-F =24.5Hz),29.3,24.9,23.0(t,CF,J=4.1Hz),13.5. 19 F NMR (376MHz, CDCl3) δ-104.1 (ddt, J=247.2, 25.9, 9.9Hz), -105.8 (ddt, J=244.4, 25.6, 8.8Hz). MS (ESI): m / z (%) 472.2 ([M+H] + ).HRMS: Calculated value C 31 H 32 NF2O: 472.2447; Measured value: 472.2450. IR (thin slice) νmax 3025, 2944, 1716cm -1 .
[0450]
[0451] Compound 19j was purified by column chromatography (petroleum ether / ethyl acetate = 50:1) to give 69 mg of a yellow oil with a yield of 65%. 1 HNMR (500MHz, CDCl3) δ7.61(d,J=7.5Hz,1H),7.58(d,J=7.6Hz,1H),7.41(d,J=7.4Hz,1H),7.36–7. 28(m,5H),7.25(t,J=6.9Hz,2H),7.21(t,J=8.8Hz,3H),7.03(t,J=7.5Hz,1H),6.89(d,J=8.1Hz,2H ),6.80(d,J=7.5Hz,1H),4.79(s,1H),3.48(qd,J=9.5,4.0Hz,1H),3.00(dd,J=14.0,4.0Hz,1H),2. 70(hept,J=7.1Hz,2H),2.47–2.32(m,1H),2.28–2.10(m,1H),2.00–1.82(m,3H),1.55(s(br),1H). 13C NMR (126MHz, CDCl3) δ146.3,146.0,141.6,140.02,139.94,137.3,131.6,131.0,128.43,128.41,128.1,128.0,127.4,127.1,126.2(t,CF,1J C-F =245.8Hz),126.0,125.2,124.3,120.5,119.7,63.0,62.9(dd,CF,2J C-F =27.6,24.4Hz),36.6,35.4,31.5(t,CF,2J C-F =24.3Hz),22.9(t,CF,J C-F =4.0Hz). 19 F NMR (376MHz, CDCl3) δ-103.6 (ddt, J=246.0, 27.0, 8.0Hz), -106.5 (ddt, J=245.4, 28.3, 8.3Hz). MS (ESI): m / z (%) 534.1 ([M+H] + ).HRMS: Calculated value C 31 H 29 NF2Br: 532.1446; Measured value: 532.1436. IR (thin slice) νmax 2928, 1488, 804cm -1
[0452]
[0453] Compound 19k was purified by column chromatography (petroleum ether / ethyl acetate = 50:1) to give 46 mg of a yellow oil. The yield was 55%. 1 HNMR (400MHz, CDCl3) δ7.68(t,J=7.4Hz,2H),7.61(d,J=7.5Hz,1H),7.51(d,J=7.4Hz,1H),7 .42–7.34(m,2H),7.34–7.27(m,4H),7.25–7.19(m,3H),5.76–5.59(m,1H),4.98(s,1H),4.96 –4.93(m,1H),4.92–4.88(m,1H),3.39–3.28(m,1H),2.71–2.67(m,2H),2.29–2.12(m,1H),2 .13–2.01(m,2H),1.97–1.87(m,3H),1.77–1.65(m,1H),1.52(s(br),1H),1.42–1.30(m,1H). 13C NMR (126MHz, CDCl3) δ146.51,146.45,141.7,140.4,140.0,137.7,128.43,128.38,128.14,128.12,127.4,127.2,126.7(t,CF,1J C-F =245.7Hz),125.9,125.2,125.0,119.9,119.7,115.2,62.5,59.4(dd,CF,2J C-F =26.9,24.5Hz),35.5,31.7(t,CF,2J C-F =24.5Hz),30.3,30.0,23.0(t,CF,J=4.2Hz). 19 F NMR (376MHz, CDCl3) δ-103.7 (ddt, J=248.7, 28.0, 9.3Hz, 1F), -105.9 (ddt, J=245.0, 26.7, 9.3Hz, 1F). MS (ESI): m / z (%) 418.2 ([M+H] + ).HRMS: Calculated value C 28 H 30 NF2: 418.2341; Measured value: 418.2348. IR (thin sheet) νmax 3063, 2927, 1716cm -1 .
[0454]
[0455] Compound 191 (without L22) was purified by column chromatography (petroleum ether / ethyl acetate = 20:1) to give 29 mg of a yellow oil with a yield of 33%. 1 H NMR(400MHz, CDCl3) δ7.69(d,J=6.7Hz,1H),7.65(d,J=9.0Hz,1H),7.56–7.51(m ,1H),7.49(td,J=7.3,1.1Hz,1H),7.37(t,J=7.4Hz,2H),7.33–7.27(m,4H),7.22 (t,J=6.7Hz,3H),4.98(s,1H),3.50–3.36(m,1H),2.70(t,J=7.3Hz,2H),2.58–2. 38(m,2H),2.21–2.04(m,1H),2.00(s,3H),1.95–1.83(m,3H),1.65–1.50(m,3H). 13C NMR (126MHz, CDCl3) δ146.4,146.3,141.6,140.3,140.1,128.42,128.39,128.20,128.17,127.46,127.35,126.5(t,CF,1J C-F =245.5Hz),126.0,125.1,124.9,120.0,119.8,62.5,58.8(t,CF,2J C-F =25.7Hz),35.4,32.2(t,CF,2J C-F =24.6Hz),30.8,30.4,23.1(t,CF,J C-F =4.2Hz),
[0456] 15.2. 19 F NMR (376MHz CDCl3) δ-104.6 (ddt, J=246.3, 25.3, 9.7Hz, 1F), -106.4 (ddt, J=245.7, 26.4, 10.1Hz, 1F). MS (ESI): m / z (%) 438.2 ([MH] + ).HRMS: Calculated value C 27 H 30 NF2S: 438.2062; Measured value: 438.2059. IR (thin sheet) νmax 3025, 2921, 1715cm -1 .
[0457]
[0458] Compound 19m was purified by column chromatography (petroleum ether / ethyl acetate = 20:1-10:1) to give 86 mg of a yellow oil with a yield of 84%. 1 H NMR (500MHz, CDCl3) δ7.65(d,J=7.6Hz,1H),7.63(d,J=7.6Hz,1H),7.58(d,J=7.5 Hz,1H),7.47(d,J=7.4Hz,1H),7.38–7.32(m,2H),7.31–7.26(m,4H),7.25–7.17(m ,8H),4.95(s,1H),4.39(s,2H),3.40–3.28(m,3H),2.78–2.62(m,2H),2.25–2.08( m,1H),1.98–1.81(m,3H),1.74–1.57(m,3H),1.47(s(br),1H),1.40–1.29(m,1H). 13C NMR (126MHz, CDCl3) δ146.51,146.49,141.7,140.4,139.9,138.4,128.41,128.35,128.29,128.2,127.6,127.5,127.3,127.2,126.7(t,CF,1J C-F =245.3Hz),125.9,125.2,125.0,119.9,119.7,72.0,69.9,62.5,59.8(dd,J=26.8,24.5Hz),35.5,31.7(t,CF,2J C-F =24.5Hz),27.4,26.5,23.0(t,CF,J C-F =3.8Hz). 19 F NMR(376MHz, CDCl3)δ-102.3–-104.1(m),-104.5–-106.2(m).MS(ESI):m / z(%)512.3([M+H] + ).HRMS: Calculated value C 34 H 36 NF2O: 512.2760; Measured value: 512.2758. IR (thin slice) νmax 2939, 2858, 1451cm -1 .
[0459]
[0460] Compound 19n, without reduction operation, was purified by column chromatography (petroleum ether / ethyl acetate = 20:1-10:1) to obtain 79 mg of a yellow oil with a yield of 70%. 1 H NMR (400MHz, CDCl3) δ7.90(d,J=7.4Hz,1H),7.66(d,J=8.2Hz,2H),7.60(d,J=7.5Hz,1H),7.55(dd,J=7.5,5.3Hz,2H),7.44(td,J=7.4,1.2Hz,1H),7. 36(dt,J=12.9,7.5Hz,2H),7.30–7.21(m,4H),7.20–7.05(m,4H),5.73–5. 61(m,1H),2.63(hept,J=6.8Hz,2H),2.42–2.19(m,1H),2.04–1.79(m,3H). 13 C NMR (126MHz, CDCl3) δ165.2,144.1,141.7,141.2,138.2,137.4,137.0(d,CF,J C-F=4.1Hz),131.8,131.5,130.9,130.6,128.4,128.32,128.27,128.1,127.3,125.8,124.2(t,CF,1J C-F =247.4Hz),123.0,120.5,119.4,93.9,68.0(t,CF,2J C-F =27.6Hz),35.4,32.0(t,CF,2J C-F =23.8Hz),23.2(t,CF,J C-F =3.7Hz). 19 F NMR (376MHz, CDCl3) δ-103.51 (ddt, J=241.4, 26.1, 9.4Hz), -106.42 (ddt, J=241.5, 27.9, 13.9Hz). MS (ESI): m / z (%) 564.1 ([M+H] + ).HRMS: Calculated value C 30 H 25 NF2I: 564.0994; Measured value: 564.0985. IR (thin sheet) νmax 3025, 2961, 1715cm -1 .
[0461]
[0462] N-(2-([1,1'-biphenyl]-4-yl)-1-cyclopropyl-2,2-difluoroethyl)-9H-fluoren-9-amine, 0.2 mmol reaction scale, the product was purified by silica gel chromatography (petroleum ether: ethyl acetate = 50:1) to give 79 mg of a yellow oil, 90% yield. 1 H NMR(400MHz, CDCl3)7.80(d,J=8.0Hz,2H),7.77–7.66(m,7H),7.59(d,J=7.6Hz,1H),7.52(t,J=7.6Hz,2H),7.46–7.38(m,3H),7.38–7 .31(m,2H),5.16(s,1H),3.04–2.94(m,1H),1.90(s,1H),0.66–0.48(m,2H),0.44–0.35(m,1H),0.31–0.22(m,1H),0.00–-0.10(m,1H). 19 F NMR(376MHz, CDCl3)δ-99.30–-101.00(m,2F). 13C NMR (126MHz, CDCl3) δ147.2,146.2,142.4,140.4,140.3,139.9,134.6(t,J=26.5Hz),128.8,128.1,128.0,127.7,127.4,127.2,126.9(t,J=6.3H z),126.5,125.2,125.0,123.6(t,J=247.5Hz),119.9,119.7,65.9(t,J= 27.1Hz), 62.2, 12.6 (t, J = 3.9Hz), 4.0, 3.8.MS (ESI): m / z (%) 438.2 ([M+H] + ).HRMS (ESI) calculated value C 30 H 26 F2N([M+H] + ):438.2028; measured value:438.2030.
[0463]
[0464] 3-((9H-fluoren-9-yl)amino)-3-cyclopropyl-N,N-diethyl-2,2-difluoropropionamide, 0.2 mmol reaction scale, the product was purified by silica gel chromatography (petroleum ether: ethyl acetate = 10:1) to give 62 mg of a yellow oil, 41% yield. 1 H NMR (400MHz, CDCl3) δ7.71–7.63(m,4H),7.40–7.27(m,4H),5.13(s,1H),3.54–3.34(m,4H),2.84–2.72(m,1H),2.59(br, 1H),1.24–1.15(m,6H),0.98–0.84(m,1H),0.51–0.41(m,1H),0.33–0.24(m,1H),0.17–0.07(m,1H),-0.27–-0.36(m,1H). 19 F NMR(376MHz, CDCl3)δ-104.43–-106.10(m,2F). 13C NMR (126MHz, CDCl3) δ163.3 (t, J = 28.6Hz), 147.3, 145.4, 140.6, 139.9, 128.1, 127.8, 127.3, 127.1, 125.2, 125.1, 119.8, 119.6, 118. 5(t,J=259.8Hz),63.3(t,J=22.5Hz),62.2,42.1(t,J=6.7Hz),41.9,14.4,12.3,11.9(t,J=3.7Hz),3.7.MS(ESI):m / z(%)385.2([M+H] + ).HRMS (ESI) calculated value C 23 H 27 F2ON2([M+H] + ):385.2086; Measured value:385.2089.
[0465]
[0466] N-(1-cyclopropyl-2,2-difluoro-4-(triethylsilyl)but-3-yn-1-yl)-9H-fluoren-9-amine, 0.2 mmol reaction scale, the product was purified by silica gel chromatography (petroleum ether: ethyl acetate = 50:1) to give 72 mg of a yellow oil, 85% yield. 1 H NMR (400MHz, CDCl3) δ7.74–7.67(m,3H),7.60(d,J=7.2Hz,1H),7.42–7.35(m,2H),7.35–7.28(m,2H),5.14(s,1H),2.89–2.81(m,1H),1.94(br,1 H),1.06(t,J=8.0Hz,9H),1.02–0.87(m,1H),0.71(q,J=8.0Hz,6H),0.6 6–0.59(m,1H),0.58–0.49(m,1H),0.41–0.28(m,1H),0.09–0.01(m,1H). 19 F NMR (376MHz, CDCl3) δ-87.67 (dd, J=274.7, 6.7Hz, 1F), -88.90 (dd, J=275.0, 8.9Hz, 1F). 13C NMR (126MHz, CDCl3) δ147.1,146.6,140.3,139.9,128.03,127.96,127.3,127.2,125.3,124.7,119.9,119.6,115.7 (t, J=238. 0Hz),97.6(t,J=37.7Hz),92.2(t,J=5.3Hz),65.6(t,J=28.5Hz),62.1,12.3,12.2,7.3,3.9,3.1.MS(ESI):m / z(%)424.2([M+H] + ).HRMS (ESI) calculated value C 26 H 32 F2NSi([M+H] + ):424.2267; Measured value:424.2264.
[0467]
[0468] Ethyl 4-(1-((9H-fluoren-9-yl)amino)-2,2-difluoro-4-(triethylsilyl)but-3-yn-1-yl)benzoate, 0.2 mmol reaction scale, the product was purified by silica gel chromatography (petroleum ether: ethyl acetate = 50:1) to give 53 mg of a yellow oil, 47% yield. 1 H NMR(400MHz, CDCl3)δ7.91(d,J=7.6Hz,2H),7.71–7.65(m,3H),7.49(d,J=7.6Hz, 1H),7.41–7.34(m,2H),7.33–7.23(m,2H),7.10(d,J=8.0Hz,2H),5.13(s,1H),4.3 7(q,J=7.2Hz,2H),3.57–3.32(m,1H),2.86–2.68(m,2H),2.16–2.05(m,1H),1.76 –1.62(m,2H),1.39(t,J=7.2Hz,3H),1.01(t,J=7.6Hz,9H),0.67(q,J=7.6Hz,6H). 19 F NMR (376MHz, CDCl3) δ-88.04 (d, J = 275.6Hz), -89.58 (dd, J = 275.6, 10.4Hz, 1F). 13CNMR (126MHz, CDCl3) δ166.5,146.7,146.6,146.3,140.2,140.2,129.7,128.3,128.1,127.4,127.3,125.0,124.9,120.0,119.8,116 .1(t,J=238.5Hz),97.0(t,J=38.0Hz),93.1,62.3,61.1(t,J=25.3Hz),60.8,32.5,32.1,14.3,7.3,3.8.MS(ESI):m / z(%)560.3([M+H] + ).HRMS (ESI) calculated value C 34 H 40 F2NO2Si([M+H] + ):560.2791; Measured value:560.2789.
[0469]
[0470] N-(1-([1,1'-biphenyl]-4-yl)-1,1-difluoro-4-(5-methylfuran-2-yl)butan-2-yl)-9H-fluoren-9-amine, 0.2 mmol reaction scale, the product was purified by silica gel chromatography (petroleum ether: ethyl acetate = 50:1) to give 87 mg of a yellow oil, 86% yield. 1 H NMR (400MHz, CDCl3) δ7.74–7.63(m,9H),7.53–7.48(m,2H),7.47–7.36(m,4H),7.37–7.28(m,1H),7.23(d,J=7.6Hz,1H),5.85–5.82( m,1H),5.74(d,J=3.2Hz,1H),5.00(s,1H),3.79–3.66(m,1H),2.72–2.56(m,2H),2.23(s,3H),2.10–1.97(m,1H),1.65–1.54(m,2H). 19 F NMR (376MHz, CDCl3) δ-101.80 (dd, J=245.7, 9.8Hz, 1F), -103.01 (dd, J=245.7, 11.1Hz, 1F). 13C NMR (126MHz, CDCl3) δ153.2,150.3,146.4,146.3,142.6,140.3,140.24,140.1,134 .5(t,J=26.5Hz),128.9,128.2,128.0,127.7,127.4,127.20,127.18,126.8,126.6( t,J=6.2Hz),125.15,125.05,123.8(t,J=247.4Hz),119.9,119.7,105.8,105.7,62 .7,60.7(t,J=27.4Hz),29.4(t,J=2.8Hz),24.6,13.4.MS(ESI):m / z(%)506.2([M+H] + ).HRMS (ESI) calculated value C 34 H 30 F2NO([M+H] + ):506.2290; Measured value:506.2294.
[0471]
[0472] N-(4,4-difluoro-1-(5-methylfuran-2-yl)-6-(triethylsilyl)hexyl-5-yn-3-yl)-9H-fluoren-9-amine, 0.2 mmol reaction scale, the product was purified by silica gel chromatography (petroleum ether: ethyl acetate = 50:1) to give 74 mg of a yellow oil, 75% yield. 1 H NMR (400MHz, CDCl3) δ7.75–7.67(m,3H),7.56(d,J=7.2Hz,1H),7.39(t,J=7.6Hz,2H),7.36–7.25(m,2H),5.89–5.85(m,2H),5.14(s,1H),3.69–3 .57(m,1H),2.79(t,J=8.0Hz,2H),2.27(s,3H),2.25–2.16(m,1H),1.78– 1.67(m,1H),1.65(br,1H),1.05(t,J=8.0Hz,9H),0.71(q,J=8.0Hz,6H). 19 F NMR (376MHz, CDCl3) δ-88.36 (dd, J=275.1, 6.1Hz, 1F), -90.15 (dd, J=275.0, 10.7Hz, 1F). 13C NMR (126MHz, CDCl3) δ153.2,150.4,147.3,146.4,140.1,140.03,128.2,128.0,127.4,127.3,125.1,124.8,119.9,119.7,116.3(t,J=238.4),1 05.8,105.7,97.2(t,J=38.2Hz),93.03(t,J=5.2Hz),62.6,61.5(dd,J=26.3,24.3Hz),29.5,24.5,13.5,7.3,3.9.MS(ESI):m / z(%)492.3([M+H] + ).HRMS (ESI) calculated value C 30 H 36 F2NOSi([M+H] + ):492.2529; measured value:492.2524.
[0473]
[0474] Tert-butyl 3-(1-((9H-fluoren-9-yl)amino)-2,2-difluoro-4-(triethylsilyl)but-3-yn-1-yl)azetidine-1-carboxylate, 0.2 mmol reaction scale, the product was purified by silica gel chromatography (petroleum ether: ethyl acetate = 20:1) to give 92 mg of a yellow oil, 85% yield. 1 H NMR (400MHz, CDCl3) δ7.74–7.66(m,3H),7.63(d,J=7.2Hz,1H),7.39(t,J=7.2Hz,2H),7.35–7.29(m,2H),5.16(s,1H),4.07–3.93(m,2H ),3.87(d,J=7.2Hz,2H),3.82–3.72(m,1H),3.00–2.81(m,1H),1.73(s,1H),1.43(s,9H),1.04(t,J=8.0Hz,9H),0.70(q,J=8.0Hz,6H). 19 F NMR (376MHz, CDCl3) δ-86.56 (d, J = 299.1Hz, 1F), -87.89 (dd, J = 278.9, 8.9Hz, 1F). 13C NMR (126MHz, CDCl3) δ156.1,147.0,145.8,140.2,134.0,128.4,128.1,127.45,127.40,125.0,124.5,120.0,119.7,115 .7(t,J=240.1Hz),96.4(t,J=37.6Hz),94.1,79.3,63.8,62.4,51.2,29.9,28.3,7.2,3.7.MS(ESI):m / z(%)539.3([M+H] + ).HRMS (ESI) calculated value C 31 H 41 F2N2O2Si([M+H] + ):539.2900; Measured value:539.2896.
[0475]
[0476] N-(2,2-difluoro-1-(4-iodophenyl)-4-(triethylsilyl)but-3-yn-1-yl)-9H-fluorene-9-imine, the product was not reduced, 0.2 mmol reaction scale, the product was purified by silica gel chromatography (petroleum ether: ethyl acetate = 100: 1) to give 83 mg of a yellow oil, 71% yield. 1 H NMR (400MHz, CDCl3) δ7.97(d,J=7.6Hz,1H),7.68(d,J=8.4Hz,2H),7.59(t,J=7.2Hz,2H),7.55(d,J=7.2Hz,1H) ,7.45–7.31(m,5H),7.18(t,J=7.7Hz,1H),5.79(t,J=9.2Hz,1H),0.95(t,J=8.0Hz,9H),0.60(q,J=8.0Hz,6H). 19 FNMR (376MHz, CDCl3) δ-88.55 (dd, J=270.3, 8.5Hz, 1F), -91.25 (dd, J=270.3, 10.0Hz, 1F). 13C NMR (126MHz, CDCl3) δ165.4,144.2,141.2,138.3,137.3,135.9(d,J=3.2Hz),131.9,131.5,131.1,131.0,128.4,128.0,127.3,123.3,12 0.5,119.3,113.5(t,J=237.6),96.6(t,J=37.5Hz),94.5,93.7(t,J=5.4Hz),69.4(t,J=27.8Hz),7.2,3.8.MS(ESI):m / z(%)506.2([M+H] + ).HRMS (ESI) calculated value C 34 H 30 F2NO([M+H] + ):506.2290; measured value:506.2294.
[0477]
[0478] N-(2-([1,1'-biphenyl]-4-yl)-2,2-difluoro-1-(4-iodophenyl)ethyl)-9H-fluorene-9-imine, the product was not reduced, 0.2mmol reaction scale, the product was purified by silica gel chromatography (petroleum ether: ethyl acetate = 100:1) to give 59mg of yellow oil, 50% yield. 1 H NMR (400MHz, CDCl3) δ7.92 (d, J=7.2Hz, 1H), 7.65–7.57 (m, 8H), 7.56–7.43 (m, 6H), 7.4 1–7.33(m,3H),7.22–7.16(m,1H),7.13(d,J=8.0Hz,2H),5.99(dd,J=11.2,8.4Hz,1H). 19 F NMR (376MHz, CDCl3) δ-97.29 (d, J=242.1Hz, 1F), -103.11 (dd, J=242.4, 10.9Hz, 1F). 13C NMR (126MHz, CDCl3) δ165.0,144.1,142.4,141.1,140.2,138.4,137.1,136.6 (d,J=4.3Hz),133.4(t,J=26.2Hz),131.8,131.5,131.0,130.9,128.8,128.4 ,128.0,127.6,127.5(t,J=6.2Hz),127.3,127.2,126.0,123.0,121.7(t,J=2 48.5),120.5,119.4,94.1,69.6(t,J=30.5Hz).MS(ESI):m / z(%)506.2([M+H] + ).HRMS (ESI) calculated value C 34 H 30 F2NO([M+H] + ):506.2290; measured value:506.2294.
[0479] Example 7 Reaction Application Study
[0480] 1. Gram-scale reaction
[0481]
[0482] Referring to the reaction conditions of Example 6, L22 (62 mg, 12 mol%) and 16a (1.13 g, 3.75 mmol, 1.5 equiv) were added to a 25 mL sealed tube, and NiCl2·DME (55 mg, 10 mol%) was added to the sealed tube in a glove box. The sealed tube was taken out of the glove box and connected to a double row, and the gas was replaced three times. Tetrahydrofuran (8 mL) was added under an argon atmosphere and pre-stirred for 20 minutes. Subsequently, LiHMDS (3.75 mL, 1.0 M LiHMDS in THF solution, 1.5 equiv) was added dropwise to the sealed tube at 0°C. After the addition was complete, 17a (2.5 mmol, 1.0 equiv) was added and rinsed with tetrahydrofuran (2 mL). The reaction was returned to room temperature for 2 hours. After the reaction, NaBH4 (234 mg, 3.0 equiv) was added to the reaction system, and dichloromethane (10 mL) was diluted. Glacial acetic acid (2.2 mL, 20 equiv) was slowly added dropwise. At this time, the system was turbid and a large number of bubbles emerged. After stirring at room temperature for 1 hour, 10% sodium hydroxide aqueous solution (16 mL) was added to the system. Stirring was continued at room temperature for 20 minutes, and the system gradually became clear. The aqueous phase was extracted with dichloromethane (25 mL × 3), and the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated by column chromatography (petroleum ether / ethyl acetate = 10:1) to obtain the target product 18a 960 mg, with a yield of 82%.
[0483] Example 8. Reaction Application
[0484]
[0485] Compound 20, referring to the reaction conditions of Example 6, added L22 (7.4 mg, 12 mol%) and 16p (0.45 mmol, 1.5 equiv) to a 25 mL sealed tube, took the sealed tube into a glove box and added NiCl2·DME (6.6 mg, 10 mol%). The sealed tube was taken out of the glove box and connected to a double row, the gas was replaced three times, tetrahydrofuran (2 mL) was added under an argon atmosphere, and pre-stirred for 20 minutes. Subsequently, LiHMDS (0.45 mL, 1.0 M LiHMDS in THF solvent, 1.5 equiv) was added dropwise to the sealed tube at 0°C. After the addition was complete, 17l (66 mg, 0.3 mmol, 1.0 equiv) was added and rinsed with tetrahydrofuran (1 mL). The reaction was returned to room temperature for 2 hours. After the reaction was completed, fluorobenzene was first added as an internal standard to determine the crude yield (about 90%). Subsequently, 0.5 mL of 1 M hydrochloric acid was added to the reaction system, and TLC was used to monitor the hydrolysis of the imine. After the hydrolysis is completed, 2 mL of water is added for dilution and the tetrahydrofuran is removed by concentration. The aqueous phase is first extracted with ether (25 mL × 3) to remove fluorenone, and then the pH is adjusted to > 9 with 1M sodium hydroxide aqueous solution. Extract with dichloromethane (25 mL × 3), combine the organic phases, dry over anhydrous sodium sulfate, filter, and concentrate to obtain primary ammonia. DMAP (2.7 mg, 10 mol%), N-Boc-L-piperidine-2-carboxylic acid (140 mg, 1.5 equiv), N,N'-dicyclohexylcarbodiimide (124 mg, 2.0 equiv) are added to the dry dichloromethane (2 mL) solution of primary ammonia, and reacted at room temperature for 24 hours. After the reaction is completed, the generated solid is removed by filtration, rinsed with dichloromethane, and the filtrate is directly concentrated by column chromatography (petroleum ether / ethyl acetate = 5:1) to obtain the target product 20 64 mg, yellow oily liquid, with a yield of 50% (three-step yield). The diastereomeric mixture dr = 1.25:1. 1H NMR(500MHz, CDCl3)δ7.36–7.27(m,5H),6.31(s(br),1H),(5.99(s(br),1H)),4.94–4.6 5(m,1H),4.41–4.26(m,1H),4.25–4.14(s(br),1H),(4.05–3.95(s(br),1H)),3.26–3.0 1(m,2H),2.78(s(br),1H),2.28(s(br),1H),1.78–1.71(m,1H),1.70–1.59(m,3H),1.58 –1.52(m,1H),1.49(s,9H),1.44–1.37(m,3H),1.33–1.27(m,1H),0.90(t,J=7.3Hz,3H). 13 C NMR(126MHz, CDCl3)δ171.5(171.0),156.3(154.6),132.1,130.5,128.30(128.25),127.32(127.25),122.45(t,CF,1J C-F =247.5Hz)(122.37,t,CF,1J C-F =247.5Hz),80.7,60.3,55.53(53.54),51.6(dd,J=29.4,24.2Hz),42.4(41.3),40.45(t,CF,J C-F =24.9Hz)(40.41,t,CF,J C-F =24.9Hz)),30.1(29.9),28.2,25.2(24.8),20.4,18.7(18.6),13.6. 19 F NMR(470MHz, CDCl3)δ-103.0–-114.0(m).MS(ESI):m / z(%)425.3([M+H] + ).HRMS: Calculated value C 23 H 35 NF2O: 425.2610; Measured value: 425.2602. IR (thin slice) νmax 2937, 2872, 1682cm -1
[0486]
[0487] Compound 19p, referring to the reaction conditions of Example 6, added L22 (4.9 mg, 12 mol%) and 16q (91 mg, 0.3 mmol, 1.5 equiv) to a 25 mL sealed tube, and the sealed tube was taken into a glove box and NiCl2·DME (4.4 mg, 10 mol%) was added. The sealed tube was taken out of the glove box and connected to a double row, and the gas was replaced three times. Tetrahydrofuran (1 mL) was added under an argon atmosphere and pre-stirred for 20 minutes. Subsequently, LiHMDS (0.3 mL, 1.0 M LiHMDS in THF solvent, 1.5 equiv) was added dropwise to the sealed tube at 0°C. After the addition was complete, 17k (50 mg, 0.2 mmol, 1.0 equiv) was added and rinsed with tetrahydrofuran (1 mL). The mixture was returned to room temperature and reacted for 2 hours. After the reaction was completed, the residue was directly concentrated and subjected to column chromatography (wet loading, petroleum ether / ethyl acetate = 10:1) to obtain 66 mg of a yellow oily substance 19p with a yield of 70%. 1 H NMR (400MHz, CDCl3) δ7.84 (dd, J=7.5, 1.1Hz, 1H), 7.59 (t, J=8.2Hz, 2H), 7.5 9–7.52(m,1H),7.48(d,J=8.6Hz,2H),7.42(t,J=7.5Hz,1H),7.37(t,J=7.5H z,1H),7.30(t,J=7.6Hz,3H),7.17–7.06(m,6H),5.99–5.88(m,1H),4.57(d, J=12.0Hz,1H),4.42(d,J=12.0Hz,1H),4.06–3.93(m,1H),3.84–3.68(m,1H). 13 C NMR (126MHz, CDCl3) δ165.47,144.08,141.23,138.28,136.95,134.88,1 34.67,133.93,131.84,131.51,131.01,130.35,128.46,128.42,128.24 ,128.10,127.73,127.69,127.49,123.03,121.29(d,J=3.7Hz),120.40, 119.36, 73.73, 68.43 (dd, J = 34.8, 26.5Hz), 64.56 (dd, J = 27.9, 22.2Hz). 19 F NMR (376MHz, CDCl3) δ-110.6 (ddt, J=253.8, 20.6, 12.0Hz, 1F), -117.4 (ddt, J=253.9, 16.9, 8.1Hz, 1F). MS (ESI): m / z (%) 474.1 ([M+H] +).HRMS: Calculated value C 29 H 23 ClF2ON:474.1431; Measured value:474.1423.IR (thin slice)νmax 1716,1649,809cm -1
[0488]
[0489] Compound 19q, refer to the reaction conditions of Example 6, add L22 (4.9 mg, 12 mol%) and 9r (62 mg, 0.3 mmol, 1.5 equiv) to a 25 mL sealed tube, take the sealed tube into a glove box and add NiCl2·DME (4.4 mg, 10 mol%). Take the sealed tube out of the glove box and connect it to a double row, replace the gas three times, add tetrahydrofuran (1 mL) under argon atmosphere, and pre-stir for 20 minutes. Then, add LiHMDS (0.3 mL, 1.0 M LiHMDS in THF solution, 1.5 equiv) dropwise to the sealed tube at 0°C. After the addition is complete, add 6e (41 mg, 0.2 mmol, 1.0 equiv) and rinse with tetrahydrofuran (1 mL). Return to room temperature and react for 2 hours. After the reaction, NaBH4 (24 mg, 3.0 equiv) was added to the reaction system, and dichloromethane (3 mL) was diluted, and glacial acetic acid (0.22 mL, 20 equiv) was slowly added dropwise. At this time, the system was turbid and a large number of bubbles emerged. After stirring at room temperature for 1 hour, 10% sodium hydroxide aqueous solution (1.6 mL) was added to the system. Stirring was continued at room temperature for 20 minutes, and the system gradually became clear. The aqueous phase was extracted with dichloromethane (25 mL × 3), and the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and column chromatography (petroleum ether / ethyl acetate = 10:1) was used to obtain 66 mg of colorless oil with a yield of 90%. 1 H NMR(400MHz, CDCl3)δ7.64(d,J=7.5Hz,2H),7.54–7.47(m,3H),7.45–7.36(m,3H),7.36–7.28(m,3H),7.2 6(t,J=7.4Hz,1H),7.23–7.16(m,1H),4.86(s,1H),3.45–3.30(m,1H),1.58(s,1H),1.02(d,J=6.7Hz,3H). 13 C NMR (101MHz, CDCl3) δ146.4,145.5,140.4,140.1,135.6(t,CF,2J C-F =26.4Hz),129.6,128.1,127.9(2C),127.27,127.20,126.3(t,CF,3J C-F=6.4Hz),125.2,125.1,122.3(t,CF,1J C-F =247.8Hz), 119.76, 119.72, 62.5, 56.3 (t, J = 28.7Hz), 16.6 (t, J = 3.5Hz). 19 F NMR (376MHz, CDCl3) δ-102.5 (dd, J=243.8, 9.4Hz), -108.5 (dd, J=243.8, 12.7Hz). MS (ESI): m / z (%) 336.2 ([M+H] + ).HRMS: Calculated value C 22 H 20 F2N:336.1558; Measured value:336.1563.IR (thin sheet)νmax3064,2980,1717cm -1 .
Claims
1. A method for preparing a compound of formula I, characterized in that: The method comprises the following steps: in a solvent, under the action of MHMDS, a nickel salt or a nickel complex and a ligand, coupling a compound represented by formula II and a compound represented by formula III to obtain a compound represented by formula I; in, M is Na, K or Li; The ligand is a compound represented by formula L for R 3 H or for R 4 is H or C1-C6 alkyl; X is Cl, Br or I; Y is fluorenyl; L1 and L2 are each independently a C1-C6 alkylene group or a chemical bond; R 1 For hydrogen, halogen, cyano, hydroxyl, C6~C 14 Aryl, C5~C 12 Heteroaryl, C3~C 12 Cycloalkyl, C3~C 12 Heterocycloalkyl, -NHR 1-1 、-OR 1-2 , -(C=O)-R 1-3 , by one or more R 1-4 Replacement C3~C 12 Heterocycloalkyl, By one or more R 1b Substituted C6~C 14 Aryl or one or more R 1c Substituted C5~C 12 heteroaryl; Each R 1-4 Each is independently an amino protecting group; R 1-1 and R 1-2 Each independently is a C1-C6 alkyl group, 1-1-1 Substituted C1-C6 alkyl, -Si(R 1-1-2 )3 or -(C=O)-R 1-1-3 ; Each R 1-1-1 Each independently is C6~C 14 Aryl or C5~C 12 heteroaryl; Each R 1-1-2 Each is independently a C1-C6 alkyl group; R 1-3 and R 1-1-3 Each independently is a C1-C6 alkyl group, 1-3-1 Substituted C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C 14 Aryl, C5~C 12 Heteroaryl, one or more R 1-3-2 Replacement C6~C 14 Aryl, one or more R 1-3-3 Replacement C5~C 12 Heteroaryl or Each R 1-3-1 Each of C6~C 14 Aryl, one or more R 1-3-1-1 Replacement C6~C 14 Aryl, C5~C 12 Heteroaryl or one or more R 1-3-1-2 Replacement C5~C 12 heteroaryl; Each R 1-3-1-1 and R 1-3-1-2 Each independently represents a C1-C6 alkyl group, a C1-C6 alkoxy group, a C1-C6 alkylthio group or -(C=O)-R a ; R a C6~C 14 Aryl, C5~C 12 Heteroaryl, C6~C 14 Aryl or C5~C 12 heteroaryl; Each R 1-3-2 are each independently cyano, hydroxyl or halogen; Each R 1-3-3 Each independently is a C1-C6 alkyl, a C6-C 14 Aryl, C5~C 12 Heteroaryl, one or more R 1-3-3-1 Replacement C6~C 14 Aryl or one or more R 1-3-3-2 Replacement C5~C 12 heteroaryl; Each R 1-3-3-1 and R 1-3-3-2 Each is independently cyano, hydroxyl, halogen, C1-C6 alkylthio or C1-C6 alkoxy; R 1a is C1~C6 alkyl or -Si(R 1a-1 )3, each R 1a-1 Each is independently a C1-C6 alkyl group; R 1b and R 1c Each independently is C6-C 14 Aryl or C5-C 12 heteroaryl; R 1d and R 1e Each independently is H or C1-C6 alkyl; R 2 is hydrogen, halogen, cyano, hydroxyl, C1-C6 alkyl, C2-C6 alkenyl, C6-C 14 Aryl, C5~C 12 Heteroaryl, C3~C 12 Cycloalkyl, C3~C 12 Heterocycloalkyl, C3~C 12 Cycloalkenyl, with one or more R 2-1 Replacement C6~C 14 Aryl, one or more R 2-2 Replacement C5~C 12 Heteroaryl, C1-C6 alkoxy, C1-C6 alkylthio, -OR 2-3 or one or more R 2-4 Replacement C3~C 12 Heterocycloalkyl; each R 2-4 Each is independently an amino protecting group; Each R 2-1 and R 2-2 Each is independently -(C=O)-O-C1~C6 alkyl, C1~C6 alkyl, cyano, halogen or hydroxyl; R 2-3 is C1-C6 alkyl or is replaced by one or more R 2-3-1 Substituted C1-C6 alkyl; Each R 2-3-1 Each independently is C6~C 14 Aryl or C5~C 12 heteroaryl; Each of the C5~C 12 Heteroaryl and C3~C 12 In the heterocycloalkyl group, the heteroatom is selected from one or more of N, O and S, and the number of the heteroatoms is 1, 2 or 3.
2. The method for preparing the compound of formula I as claimed in claim 1, characterized in that: The method comprises the following steps: in a solvent, under the action of MHMDS, a nickel salt or a nickel complex and a ligand, a compound represented by formula II and a compound represented by formula III are subjected to coupling reaction to obtain the compound represented by formula I; in, M is Na, K or Li; The ligand is a compound represented by formula L for R 3 H or for R 4 is H or C1-C6 alkyl; X is Cl, Br or I; Y is fluorenyl; L1 and L2 are each independently a C1-C6 alkylene group or a chemical bond; R 1 For hydrogen, halogen, cyano, hydroxyl, C6~C 14 Aryl, C5~C 12 Heteroaryl, C3~C 12 Cycloalkyl, C3~C 12 Heterocycloalkyl, -NHR 1-1 、-OR 1-2 、-(C=O)-R 1-3 or one or more R 1-4 Replacement C3~C 12 Heterocycloalkyl; Each R 1-4 Each is independently an amino protecting group; R 1-1 and R 1-2 Each independently is a C1-C6 alkyl group, 1-1-1 Substituted C1-C6 alkyl, -Si(R 1-1-2 )3 or -(C=O)-R 1-1-3 ; Each R 1-1-1 Each independently is C6~C 14 Aryl or C5~C 12 heteroaryl; Each R 1-1-2 Each is independently a C1-C6 alkyl group; R 1-3 and R 1-1-3 Each independently is a C1-C6 alkyl group, 1-3-1 Substituted C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C 14 Aryl, C5~C 12 Heteroaryl, one or more R 1-3-2 Replacement C6~C 14 Aryl or one or more R 1-3-3 Replacement C5~C 12 heteroaryl; Each R 1-3-1 Each of C6~C 14 Aryl, one or more R 1-3-1-1 Replacement C6~C 14 Aryl, C5~C 12 Heteroaryl or one or more R 1-3-1-2 Replacement C5~C 12 heteroaryl; Each R 1-3-1-1 and R 1-3-1-2 Each independently represents a C1-C6 alkyl group, a C1-C6 alkoxy group, a C1-C6 alkylthio group or -(C=O)-R a ; R a C6~C 14 Aryl, C5~C 12 Heteroaryl, C6~C 14 Aryl or C5~C 12 heteroaryl; Each R 1-3-2 are each independently cyano, hydroxyl or halogen; Each R 1-3-3 Each independently is a C1-C6 alkyl, a C6-C 14 Aryl, C5~C 12 Heteroaryl, one or more R 1-3-3-1 Replacement C6~C 14 Aryl or one or more R 1-3-3-2 Replacement C5~C 12 heteroaryl; Each R 1-3-3-1 and R 1-3-3-2 Each is independently cyano, hydroxyl, halogen, C1-C6 alkylthio or C1-C6 alkoxy; R 2 is hydrogen, halogen, cyano, hydroxyl, C1-C6 alkyl, C2-C6 alkenyl, C6-C 14 Aryl, C5~C 12 Heteroaryl, C3~C 12 Cycloalkyl, C3~C 12 Heterocycloalkyl, C3~C 12 Cycloalkenyl, with one or more R 2-1 Replacement C6~C 14 Aryl, one or more R 2-2 Replacement C5~C 12 Heteroaryl, C1-C6 alkoxy, C1-C6 alkylthio, -OR 2-3 or one or more R 2-4 Replacement C3~C 12 Heterocycloalkyl; each R 2-4 Each is independently an amino protecting group; Each R 2-1 and R 2-2 Each is independently -(C=O)-O-C1~C6 alkyl, C1~C6 alkyl, cyano, halogen or hydroxyl; R 2-3 is C1-C6 alkyl or is replaced by one or more R 2-3-1 Substituted C1-C6 alkyl; Each R 2-3-1 Each independently is C6~C 14 Aryl or C5~C 12 heteroaryl; Each of the C5~C 12 Heteroaryl and C3~C 12 In the heterocycloalkyl group, the heteroatom is selected from one or more of N, O and S, and the number of the heteroatoms is 1, 2 or 3.
3. The method for preparing the compound of formula I as claimed in claim 1 or 2, characterized in that: It meets one or more of the following conditions: (1) M is Li; (2) for For example (3) for For example (4)R 3 H or For example, H; (5)R 4 is H or C1-C6 alkyl, for example, C1-C6 alkyl; (6) The compound represented by formula L is For example Preferably (7) The nickel salt is Ni(T)2 or a DME complex of Ni(T)2, where T is a halogen, for example, a DME complex of Ni(T)2, where T is a halogen; (8) The nickel complex is a COD complex of nickel; (9) X is I or Br; (10)R 1 Halogen, cyano, C6~C 14 Aryl, C3~C 12 Cycloalkyl, C3~C 12 Heterocycloalkyl, with one or more R 1-4 Replacement C3~C 12 Heterocycloalkyl, -NHR 1-1 、-OR 1-2 or -(C=O)-R 1-3 ; (11)R 1-1 and R 1-2 Each independently is one or more R 1-1-1 Substituted C1-C6 alkyl, -Si(R 1-1-2 )3 or -(C=O)-R 1-1-3 ; (12) Each R 1-1-1 Each independently is C6~C 14 Aryl; (13)R 1-3 and R 1-1-3 Each independently is one or more R 1-3-1 Substituted C1-C6 alkyl, C1-C6 alkoxy, one or more R 1-3-2 Replacement C6~C 14 Aryl or one or more R 1-3-3 Replacement C5~C 12 heteroaryl; (14) Each R 1-3-1 Each independently is one or more R 1-3-1-2 Replacement C5~C 12 heteroaryl; (15) Each R 1-3-1-1 and R 1-3-1-2 Each independently represents a C1-C6 alkyl group, a C1-C6 alkoxy group or -(C=O)-R a ; (16)R a C6~C 14 Aryl; (17) Each R 1-3-2 are each independently a halogen; (18) Each R 1-3-3 Each independently is a C1-C6 alkyl group or is replaced by one or more R 1-3-3-1 Replacement C6~C 14 Aryl; (19) Each R 1-3-3-1 Each is independently cyano or C1-C6 alkoxy; (20)R 2 is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C6-C 14 Aryl, C3~C 12 Cycloalkyl, C3~C 12 Heterocycloalkyl, C3~C 12 Cycloalkenyl, with one or more R 2-1 Replacement C6~C 14 Aryl, one or more R 2-2 Replacement C5~C 12 Heteroaryl, C1-C6 alkylthio, -OR 2-3 or one or more R 2-4 Replacement C3~C 12 Heterocycloalkyl; (21) Each R 2-1 and R 2-2 Each is independently -(C=O)-O-C1~C6 alkyl, C1~C6 alkyl or halogen; (22)R 2-3 For one or more R 2-3-1 Substituted C1-C6 alkyl; and (23) Each R 2-3-1 Each independently is C6~C 14 Aryl.
4. The method for preparing the compound of formula I as claimed in claim 1 or 2, characterized in that: It meets one or more of the following conditions: (1) The coupling reaction is carried out under the action of the nickel salt and the ligand, for example, under the action of a Ni(T)2 DME complex and a ligand; (2)R 1 Halogen, cyano, C6~C 14 Aryl, C3~C 12 Cycloalkyl, C3~C 12 Heterocycloalkyl, with one or more R 1-4 Replacement C3~C 12 Heterocycloalkyl, -NHR 1-1 、-OR 1-2 , -(C=O)-R 1-3 , or one or more R 1b Substituted C6~C 14 Aryl; (3)R 1-3 and R 1-1-3 Each independently is one or more R 1-3-1 Substituted C1-C6 alkyl, C1-C6 alkoxy, one or more R 1-3-2 Replacement C6~C 14 Aryl, one or more R 1-3-3 Replacement C5~C 12 Heteroaryl or (4)R 1a -Si(R 1a-1 )3; (5)R 1b and R 1c Each independently is C6-C 14 aryl; and (6)R 1d and R 1e Each is independently a C1-C6 alkyl group.
5. The method for preparing the compound of formula I as claimed in claim 1 or 2, characterized in that: It meets one or more of the following conditions: (1) In the compound represented by formula L, for (2) In ring B, for (3)R 4 wherein the C1-C6 alkyl groups are each independently methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl, such as isopropyl or tert-butyl; (4) In T, the halogen is F, Cl, Br or I, such as Cl or Br; (5) In L1 and L2, the C1-C6 alkylene groups are each independently methylene, ethylene, n-propylene, isopropylene, n-butylene, isobutylene, tert-butylene or n-pentylene, for example, methylene, ethylene, n-propylene, n-butylene or n-pentylene; (6)R 1 wherein the halogen is fluorine, chlorine, bromine or iodine, for example chlorine; (7)R 1 In the above, C6~C 14 Aryl is phenyl or naphthyl, for example phenyl; (8)R 1 In the above, C5~C 12 The heteroaryl group is a C5-C6 heteroaryl group, in which the heteroatom is preferably N and / or O, and the number of heteroatoms is preferably 1 or 2; (9)R 1 In the above, C3~C 12 Cycloalkyl is C3-C6 cycloalkyl, for example cyclohexyl; (10)R 1 In the above, C3~C 12 Heterocycloalkyl and one or more R 1-4 Replacement C3~C 12 C3~C 12 The heterocycloalkyl groups are each independently C3-C6 heterocycloalkyl groups, wherein the heteroatoms are preferably N and / or O, and the number of heteroatoms is preferably 1 or 2. The C3-C6 heterocycloalkyl groups are further preferably (11)R 1-4 wherein the amino protecting group is tert-butyloxycarbonyl, benzyloxycarbonyl, 2-biphenyl-2-propyloxycarbonyl, p-toluenesulfonyl, formyl or trifluoroacetyl, for example, tert-butyloxycarbonyl; (12)R 1-1 and R 1-2 wherein the C1-C6 alkyl group and one or more R 1-1-1 The C1-C6 alkyl groups in the substituted C1-C6 alkyl groups are each independently methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl, for example, methyl; (13)R 1-1-1 In the above, C6~C 14 Aryl is phenyl or naphthyl, for example phenyl; (14)R 1-1-1 In the above, C5~C 12 The heteroaryl group is a C5-C6 heteroaryl group, in which the heteroatom is preferably N and / or O, and the number of heteroatoms is preferably 1 or 2; (15) Each R 1-1-2 wherein the C1-C6 alkyl groups are each independently methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl, such as methyl or tert-butyl; (16)R 1-3 and R 1-1-3 wherein the C1-C6 alkyl group and one or more R 1-3-1 The C1-C6 alkyl in the substituted C1-C6 alkyl is independently methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl, for example, methyl; (17)R 1-3 and R 1-1-3 wherein the C1-C6 alkoxy group is methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy or tert-butoxy, such as ethoxy; (18)R 1-3 and R 1-1-3 wherein the C1-C6 alkylthio group is methylthio, ethylthio, n-propylthio, isopropylthio, n-butylthio, isobutylthio or tert-butylthio; (19)R 1-3 and R 1-1-3 In the above, C6~C 14 Aryl and one or more R 1-3-2 Replacement C6~C 14 C6~C 14 Aryl is each independently phenyl or naphthyl, for example phenyl; (20)R 1-3 and R 1-1-3 In the above, C5~C 12 heteroaryl and one or more R 1-3-3 Replacement C5~C 12 C5~C 12 The heteroaryl groups are each independently C5-C6 heteroaryl groups, wherein the heteroatom in the C5-C6 heteroaryl groups is preferably N and / or S, and the number of heteroatoms is preferably 1 or 2. The C5-C6 heteroaryl groups are further preferably (21) Each R 1-3-1 In the above, C6~C 14 Aryl and one or more R 1-3-1-1 Replacement C6~C 14 C6~C 14 The aryl groups are each independently phenyl or naphthyl; (22) Each R 1-3-1 In the above, C5~C 12 heteroaryl and one or more R 1-3-1-2 Replacement C5~C 12 C5~C 12 The heteroaryl groups are each independently C5 to C 10 Heteroaryl, the C5~C 10 In the heteroaryl group, the heteroatom is preferably N, the number of heteroatoms is preferably 1, and the C5 to C 10 The heteroaryl group is more preferably (23) Each R 1-3-1-1 and R 1-3-1-2 wherein the C1-C6 alkyl group is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl, for example, methyl; (24) Each R 1-3-1-1 and R 1-3-1-2 wherein the C1-C6 alkoxy group is methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy or tert-butoxy, such as methoxy; (25) Each R 1-3-1-1 and R 1-3-1-2 wherein the C1-C6 alkylthio group is methylthio, ethylthio, n-propylthio, isopropylthio, n-butylthio, isobutylthio or tert-butylthio; (26)R a In the above, C6~C 14 Aryl and C6~C 14 C6~C 14 Aryl is each independently phenyl or naphthyl, for example phenyl; (27)R a In the above, C5~C 12 Heteroaryl and C5~C 12 C5~C 12 The heteroaryl groups are each independently C5-C6 heteroaryl groups, in which the heteroatom is preferably N and / or O, and the number of heteroatoms is preferably 1 or 2; (28)R a wherein the C6-C 14 Aryl and C5~C 12 The halogen in heteroaryl is each independently fluorine, chlorine, bromine or iodine, for example chlorine; (29) Each R 1-3-2 wherein the halogen is fluorine, chlorine, bromine or iodine, for example chlorine; (30) Each R 1-3-3 wherein the C1-C6 alkyl group is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl, for example, methyl; (31) Each R 1-3-3 In the above, C6~C 14 Aryl and one or more R 1-3-3-1 Replacement C6~C 14 C6~C 14 Aryl is each independently phenyl or naphthyl, for example phenyl; (32) Each R 1-3-3 In the above, C5~C 12 heteroaryl and one or more R 1-3-3-2 Replacement C5~C 12 C5~C 12 The heteroaryl groups are each independently C5-C6 heteroaryl groups, in which the heteroatom is preferably N and / or O, and the number of heteroatoms is preferably 1 or 2; (33) Each R 1-3-3-1 and R 1-3-3-2 wherein the halogen is fluorine, chlorine, bromine or iodine; (34) Each R 1-3-3-1 and R 1-3-3-2 wherein the C1-C6 alkylthio group is methylthio, ethylthio, n-propylthio, isopropylthio, n-butylthio, isobutylthio or tert-butylthio; (35) Each R 1-3-3-1 and R 1-3-3-2 wherein the C1-C6 alkoxy group is methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy or tert-butoxy, such as tert-butoxy; (36)R 2 wherein the halogen is fluorine, chlorine, bromine or iodine, for example chlorine; (37)R 2 wherein the C1-C6 alkyl group is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl, such as methyl or isopropyl; (38)R 2 wherein the C2-C6 alkenyl group is vinyl, n-propenyl, isopropenyl, n-butenyl or 3-methyl-1-propenyl, such as vinyl; (39)R 2 In the above, C6~C 14 Aryl and one or more R 2-1 Replacement C6~C 14 C6~C 14 Aryl is each independently phenyl or naphthyl, for example phenyl; (40)R 2 In the above, C5~C 12 heteroaryl and one or more R 2-2 Replacement C5~C 12 C5~C 12 The heteroaryl groups are each independently C5-C6 heteroaryl groups, in which the heteroatom is preferably O, and the number of heteroatoms is preferably 1 or 2. The C5-C6 heteroaryl groups are further preferably (41)R 2 In the above, C3~C 12 Cycloalkyl is C3-C6 cycloalkyl, such as cyclopropyl, cyclopentyl or cyclohexyl; (42)R 2 In the above, C3~C 12 Heterocycloalkyl and one or more R 2-4 Replacement C3~C 12 C3~C 12 The heterocycloalkyl groups are each independently C3-C6 heterocycloalkyl groups, wherein the heteroatoms are preferably N and / or O, and the number of heteroatoms is preferably 1. The C3-C6 heterocycloalkyl groups are further preferably (43)R 2 In the above, C3~C 12 The cycloalkenyl group is a C3-C6 cycloalkenyl group, for example, the C3-C6 cycloalkenyl group is a cyclopropenyl group, a cyclobutenyl group, a cyclopentenyl group or a cyclohexene group, the number of unsaturated carbon-carbon double bonds in the C3-C6 cycloalkenyl group is preferably 1 or 2, and the C3-C6 cycloalkenyl group is further preferably (44)R 2 wherein the C1-C6 alkoxy group is methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy or tert-butoxy; (45)R 2 wherein the C1-C6 alkylthio group is methylthio, ethylthio, n-propylthio, isopropylthio, n-butylthio, isobutylthio or tert-butylthio, for example, methylthio; (46) Each R 2-4 wherein the amino protecting group is tert-butyloxycarbonyl, benzyloxycarbonyl, 2-biphenyl-2-propyloxycarbonyl, p-toluenesulfonyl, formyl or trifluoroacetyl, for example, tert-butyloxycarbonyl; (47) Each R 2-1 and R 2-2 wherein the -(C=O)-O-C1~C6 alkyl and the C1~C6 alkyl are each independently methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl, such as methyl or ethyl; (48) Each R 2-1 and R 2-2 wherein the halogen is fluorine, chlorine, bromine or iodine, for example chlorine, bromine or iodine; (49)R 2-3 wherein the C1-C6 alkyl group and one or more R 2-3-1 The substituted C1-C6 alkyl group is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl, for example, methyl; (50) Each R 2-3-1 In the above, C6~C 14 Aryl is phenyl or naphthyl, for example phenyl; and (51) Each R 2-3-1 In the above, C5~C 12 The heteroaryl group is a C5-C6 heteroaryl group, in which the heteroatom is preferably O and / or N, and the number of the heteroatoms is preferably 1 or 2.
6. The method for preparing the compound of formula I as claimed in claim 1 or 2, characterized in that: It meets one or more of the following conditions: (1) In the compound represented by formula L, for (2) In ring B, for (1)R 1 In the above, the one or more R 1b Substituted C6~C 14 C6~C 14 Aryl is phenyl or naphthyl, for example phenyl; (2)R 1 In the above, the one or more R 1c Substituted C5~C 12 C5~C 12 The heteroaryl group is a C5-C6 heteroaryl group, in which the heteroatom is preferably N and / or O, and the number of heteroatoms is preferably 1 or 2; (3)R 1a wherein the C1-C6 alkyl group is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl; (4)R 1a-1 wherein the C1-C6 alkyl group is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl, such as ethyl; (5)R 1b and R 1c In the above, C6~C 14 Aryl is each independently phenyl or naphthyl, for example phenyl; (6)R 1b and R 1c In the above, C5~C 12 The heteroaryl groups are each independently C5-C6 heteroaryl groups, wherein the heteroatom is preferably N and / or O, and the number of heteroatoms is preferably 1 or 2; and (7)R 1d and R 1e In the above, the C1-C6 alkyl group is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl, for example, ethyl.
7. The method for preparing the compound of formula I as claimed in claim 1 or 2, characterized in that: It is any of the following options: Solution 1: for R 3 H or for R 4 is a C1-C6 alkyl group; The nickel salt is Ni(T)2 or a DME complex of Ni(T)2; The nickel complex is a COD complex of nickel; T is a halogen; X is I or Br; Y is fluorenyl; L1 and L2 are each independently a C1-C6 alkylene group or a chemical bond; R 1 Halogen, cyano, C6~C 14 Aryl, C3~C 12 Cycloalkyl, C3~C 12 Heterocycloalkyl, with one or more R 1-4 Replacement C3~C 12 Heterocycloalkyl, -NHR 1-1 、-OR 1-2 、-(C=O)-R 1-3 , or one or more R 1b Substituted C6~C 14 Aryl; R 1-4 is an amino protecting group; R 1-1 and R 1-2 Each independently is one or more R 1-1-1 Substituted C1-C6 alkyl, -Si(R 1-1-2 )3 or -(C=O)-R 1-1-3 ; Each R 1-1-1 Each independently is C6~C 14 Aryl; Each R 1-1-2 Each is independently a C1-C6 alkyl group; R 1-3 and R 1-1-3 Each independently is one or more R 1-3-1 Substituted C1-C6 alkyl, C1-C6 alkoxy, one or more R 1-3-2 Replacement C6~C 14 Aryl, one or more R 1-3-3 Replacement C5~C 12 Heteroaryl or Each R 1-3-1 Each independently is one or more R 1-3-1-2 Replacement C5~C 12 heteroaryl; Each R 1-3-1-2 Each independently represents a C1-C6 alkyl group, a C1-C6 alkoxy group or -(C=O)-R a ; R a C6~C 14 Aryl; Each R 1-3-2 are each independently a halogen; Each R 1-3-3 Each independently is a C1-C6 alkyl group or is replaced by one or more R 1-3-3-1 Replacement C6~C 14 Aryl; Each R 1-3-3-1 Each is independently cyano or C1-C6 alkoxy; R 1a -Si(R 1a-1 )3, each R 1a-1 Each is independently a C1-C6 alkyl group; R 1b C6-C 14 Aryl; R 1d and R 1e Each is independently a C1-C6 alkyl group; R 2 is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C6-C 14 Aryl, C3~C 12 Cycloalkyl, C3~C 12 Heterocycloalkyl, C3~C 12 Cycloalkenyl, with one or more R 2-1 Replacement C6~C 14 Aryl, one or more R 2-2 Replacement C5~C 12 Heteroaryl, C1-C6 alkylthio, -OR 2-3 or one or more R 2-4 Replacement C3~C 12 Heterocycloalkyl; R 2-4 is an amino protecting group; Each R 2-1 and R 2-2 Each is independently -(C=O)-O-C1~C6 alkyl, C1~C6 alkyl or halogen; R 2-3 For one or more R 2-3-1 Substituted C1-C6 alkyl; Each R 2-3-1 Each independently is C6~C 14 Aryl; Each of the C5~C 12 Heteroaryl and C3~C 12 In the heterocycloalkyl group, the heteroatom is selected from one or more of N, O and S, and the number of heteroatoms is 1, 2 or 3; Option 2: In the solvent, under the action of the MHMDS, the nickel salt and the ligand, the compound represented by formula II and the compound represented by formula III undergo a coupling reaction to obtain the compound represented by formula I; for R 3 is H; for R 4 is a C1-C6 alkyl group; M is Li; The nickel salt is a DME complex of Ni(T)2; T is a halogen; X is I or Br; Y is fluorenyl; L1 and L2 are each independently a C1-C6 alkylene group or a chemical bond; R 1 Halogen, cyano, C6~C 14 Aryl, C3~C 12 Cycloalkyl, C3~C 12 Heterocycloalkyl, with one or more R 1-4 Replacement C3~C 12 Heterocycloalkyl, -NHR 1-1 、-OR 1-2 、-(C=O)-R 1-3 , or one or more R 1b Substituted C6~C 14 Aryl; R 1-4 is an amino protecting group; R 1-1 and R 1-2 Each independently is one or more R 1-1-1 Substituted C1-C6 alkyl, -Si(R 1-1-2 )3 or -(C=O)-R 1-1-3 ; Each R 1-1-1 Each independently is C6~C 14 Aryl; Each R 1-1-2 Each is independently a C1-C6 alkyl group; R 1-3 and R 1-1-3 Each independently is one or more R 1-3-1 Substituted C1-C6 alkyl, C1-C6 alkoxy, one or more R 1-3-2 Replacement C6~C 14 Aryl, one or more R 1-3-3 Replacement C5~C 12 Heteroaryl or Each R 1-3-1 Each independently is one or more R 1-3-1-2 Replacement C5~C 12 heteroaryl; Each R 1-3-1-2 Each independently represents a C1-C6 alkyl group, a C1-C6 alkoxy group or -(C=O)-R a ; R a C6~C 14 Aryl; Each R 1-3-2 are each independently a halogen; Each R 1-3-3 Each independently is a C1-C6 alkyl group or is replaced by one or more R 1-3-3-1 Replacement C6~C 14 Aryl; Each R 1-3-3-1 Each is independently cyano or C1-C6 alkoxy; R 1a -Si(R 1a-1 )3, each R 1a-1 Each is independently a C1-C6 alkyl group; R 1b C6-C 14 Aryl; R 1d and R 1e Each is independently a C1-C6 alkyl group; R 2 is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C6-C 14 Aryl, C3~C 12 Cycloalkyl, C3~C 12 Heterocycloalkyl, C3~C 12 Cycloalkenyl, with one or more R 2-1 Replacement C6~C 14 Aryl, one or more R 2-2 Replacement C5~C 12 Heteroaryl, C1-C6 alkylthio, -OR 2-3 or one or more R 2-4 Replacement C3~C 12 Heterocycloalkyl; R 2-4 is an amino protecting group; Each R 2-1 and R 2-2 Each is independently -(C=O)-O-C1~C6 alkyl, C1~C6 alkyl or halogen; R 2-3 For one or more R 2-3-1 Substituted C1-C6 alkyl; Each R 2-3-1 Each independently is C6~C 14 Aryl; Each of the C5~C 12 Heteroaryl and C3~C 12 In the heterocycloalkyl group, the heteroatom is selected from one or more of N, O and S, and the number of heteroatoms is 1, 2 or 3; Option 3: In the preparation method of the compound represented by formula I, for R 3 H or for R 4 is H or C1-C6 alkyl; The nickel salt is Ni(T)2 or a DME complex of Ni(T)2; The nickel complex is a COD complex of nickel; T is a halogen; X is I or Br; Y is fluorenyl; L1 and L2 are each independently a C1-C6 alkylene group or a chemical bond; R 1 Halogen, cyano, C6~C 14 Aryl, C3~C 12 Cycloalkyl, C3~C 12 Heterocycloalkyl, with one or more R 1-4 Replacement C3~C 12 Heterocycloalkyl, -NHR 1-1 、-OR 1-2 or -(C=O)-R 1-3 ; R 1-4 is an amino protecting group; R 1-1 and R 1-2 Each independently is one or more R 1-1-1 Substituted C1-C6 alkyl, -Si(R 1-1-2 )3 or -(C=O)-R 1-1-3 ; Each R 1-1-1 Each independently is C6~C 14 Aryl; Each R 1-1-2 Each is independently a C1-C6 alkyl group; R 1-3 and R 1-1-3 Each independently is one or more R 1-3-1 Substituted C1-C6 alkyl, C1-C6 alkoxy, one or more R 1-3-2 Replacement C6~C 14 Aryl or one or more R 1-3-3 Replacement C5~C 12 heteroaryl; Each R 1-3-1 Each independently is one or more R 1-3-1-2 Replacement C5~C 12 heteroaryl; Each R 1-3-1-2 Each independently represents a C1-C6 alkyl group, a C1-C6 alkoxy group or -(C=O)-R a ; R a C6~C 14 Aryl; Each R 1-3-2 are each independently a halogen; Each R 1-3-3 Each independently is a C1-C6 alkyl group or is replaced by one or more R 1-3-3-1 Replacement C6~C 14 Aryl; Each R 1-3-3-1 Each is independently cyano or C1-C6 alkoxy; R 2 is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C6-C 14 Aryl, C3~C 12 Cycloalkyl, C3~C 12 Heterocycloalkyl, C3~C 12 Cycloalkenyl, with one or more R 2-1 Replacement C6~C 14 Aryl, one or more R 2-2 Replacement C5~C 12 Heteroaryl, C1-C6 alkylthio, -OR 2-3 or one or more R 2-4 Replacement C3~C 12 Heterocycloalkyl; R 2-4 is an amino protecting group; Each R 2-1 and R 2-2 Each is independently -(C=O)-O-C1~C6 alkyl, C1~C6 alkyl or halogen; R 2-3 For one or more R 2-3-1 Substituted C1-C6 alkyl; Each R 2-3-1 Each independently is C6~C 14 Aryl; Each of the C5~C 12 Heteroaryl and C3~C 12 In the heterocycloalkyl group, the heteroatom is selected from one or more of N, O and S, and the number of the heteroatoms is 1, 2 or 3.
8. The method for preparing the compound of formula I as claimed in claim 1 or 2, characterized in that: It meets one or more of the following conditions: (1) The compound represented by formula L is For example (2)Y is (3) L1 is methylene, n-butylene, n-propylene, n-pentylene or a chemical bond; (4) L2 is methylene, ethylene, a chemical bond or n-propylene; (5)R 1 is halogen, cyano, phenyl, cyclohexane, Preferably, R 1 is halogen, cyano, phenyl, cyclohexane, and (6)R 2 is hydrogen, phenyl, Isopropyl, Vinyl, methylthio, Methyl or 9. The method for preparing the compound of formula I as claimed in claim 1 or 2, characterized in that: It meets one or more of the following conditions: (1) The compound represented by formula L is any of the following compounds: (2) The nickel complex is Ni(COD)2; (3) In the nickel salt, the DME complex of Ni(T)2 is NiCl2·DME or NiBr2·DME; (4) In the nickel salt, Ni(T)2 is NiCl2; (5) The compound represented by formula II is any of the following compounds: Preferably, the compound represented by formula II is any of the following compounds: (6) The compound represented by formula III is any of the following compounds: Preferably, the compound represented by formula III is any of the following compounds: and (7) the compound represented by formula I is any of the following compounds:
10. The method for preparing the compound of formula I according to claim 1 or 2, characterized in that: It meets one or more of the following conditions: (1) The coupling reaction is carried out in a protective gas; for example, the protective gas is argon; (3) In the coupling reaction, the solvent is an ether solvent, preferably THF; (4) In the coupling reaction, the molar volume of the compound represented by formula III and the solvent is 0.2:(0.5-10) mmol / mL, preferably 0.1:1 mmol / mL; (5) In the coupling reaction, the molar ratio of MHMDS to the compound represented by formula III is (0.5-2):1, preferably 1.5:1; (6) In the coupling reaction, the molar ratio of the nickel salt or nickel complex to the compound represented by formula III is (1-20):100, preferably 1:10; (7) In the coupling reaction, the molar ratio of the compound represented by formula L to the compound represented by formula III is (1-20):100, preferably 3:25; (8) In the coupling reaction, the molar ratio of the compound represented by formula II to the compound represented by formula III is (0.5-2):1, preferably 1.5:1; (9) The coupling reaction temperature is room temperature; the room temperature refers to 0°C to 30°C; preferably, the MHMDS is added to the reaction system at 0°C; (10) The raw materials of the coupling reaction are the solvent, the MHMDS, the nickel salt or nickel complex, the ligand, the compound represented by formula II and the compound represented by formula III; for example, the raw materials of the coupling reaction are tetrahydrofuran, LiHMDS, NiCl2 DME complex, The compound represented by formula II and the compound represented by formula III; and (11) The coupling reaction comprises the following steps: in a protective gas, mixing the nickel salt or nickel complex with a mixture of the compound represented by the formula L and the compound represented by the formula II, adding part of the solvent to obtain a mixture A, mixing the LiHMDS with the mixture A at 0°C to obtain a mixture B, mixing the remaining solvent and the compound represented by the formula III with the mixture B, and performing the coupling reaction at room temperature.
11. A method for preparing a compound represented by formula I-1, characterized in that: It includes the following steps: (1) preparing the compound of formula I according to the method for preparing the compound of formula I as described in any one of claims 1 to 10; (2) Under the action of a reducing agent, the compound represented by formula I undergoes a reduction reaction to obtain a compound represented by formula I-1; Among them, R 1 , R 2 , L1, L2 and Y are as described in any one of claims 1-10.
12. The method for preparing the compound of formula I-1 according to claim 11, characterized in that: The compound represented by formula I-1 is any of the following compounds:
13. The method for preparing the compound of formula I-1 according to claim 11, characterized in that: It meets one or more of the following conditions: (1) In the reduction reaction, the reducing agent is NaBH4; (2) In the reduction reaction, the molar ratio of the reducing agent to the compound represented by formula III is (1-10):1, preferably 3:1; (3) In the reduction reaction, the solvent of the reduction reaction is a halogenated hydrocarbon solvent, preferably DCM. Preferably, the solvent is a mixed solvent of a halogenated hydrocarbon and an ether solvent. For example, after the coupling reaction is completed, a halogenated hydrocarbon solvent is added for dilution. The halogenated hydrocarbon solvent is, for example, DCM; (4) directly carrying out the reduction reaction after the coupling reaction is completed; Preferably, the reduction reaction comprises the following steps: after the coupling reaction is completed, a reaction solution is obtained, the solvent of the reduction reaction, the reducing agent and the reaction solution are mixed, an auxiliary agent is added to carry out a reduction reaction, after the reaction is completed, a base is added, extraction, drying, filtering, concentrating, and purification are carried out to obtain the compound represented by formula I-1; and (5) The reduction reaction further comprises an auxiliary agent, preferably a Bronsted acid, such as acetic acid; For example, in the reduction reaction, the molar ratio of the auxiliary agent to the compound represented by formula III is (1-40):1, preferably 20:1; Preferably, the raw materials for the reduction reaction are the reducing agent, the solvent for the reduction reaction, the auxiliary agent and the compound shown in formula I. For example, the raw materials for the reduction reaction are NaBH4, DCM, acetic acid and the compound shown in formula I.
Citation Information
Cited By
Amino alkyl nitrile compound as well as preparation method and application thereof
CN119735525A
An aminoalkyl nitrile compound, its preparation method and application
CN119735525B
